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ABSTRACT 
Pregnancy and lactation create a large physiological demand for calcium. 
Normally, 1,25 dihydroxyvitamin D (1 ,25(0H)2D3) and the vitamin D receptor (VDR) 
are critical for the regulation of calcium and bone metabolism. Without 1,25(0H)2D3 
and/or the VDR, intestinal calcium absorption is reduced, leading to hypocalcemia, 
secondary hyperparathyroidism, rickets, and osteomalacia. This project assessed whether 
1,25(0H)2D3 and the VDR were required for the regulation of calcium and bone 
metabolism during the reproductive periods. 
Mice lacking the gene encoding for the VDR (Vdr null) and wild-type (WT) mice 
were raised on a regular 1% calcium diet until 10 weeks of age and then switched to a 2% 
calcium, 20% lactose enriched diet. Bone mineral content (BMC) was measured at 
baseline, late pregnancy, late lactation and 21 days after weaning. Duodenal 45Ca 
absorption and gene expression, parameters of calcium homeostasis, bone turnover 
markers and bone histomorphometry were measured at baseline and late pregnancy. 
Vdr null mice had a significantly lower BMC at baseline as compared to WT 
siblings. WT mice gained 7% BMC during pregnancy, lost 18% during lactation and 
recovered to baseline post weaning. In contrast, Vdr null sisters gained 57% BMC dming 
pregnancy (p:S0.05) resulting in a BMC that was equal to WT. Vdr nulls lost 31% BMC 
during lactation and recovered post-weaning to a value that was 49% higher than the pre-
pregnancy baseline. Duodenal 45Ca absorption and the expression of the calcium chrumel 
transient receptor potential, vanilloid type 6 (Trpv6) was lower in Vdr nulls at baseline 
but significantly increased to WT levels during pregnancy. Vdr null serum parathyroid 
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hormone (PTH) levels and bone turnover were elevated at baseline but normalized to WT 
levels by late pregnancy. Urine calcium concentration was reduced at baseline in Vdr 
null mice but similar to WT values during pregnancy. Vdr null rachitic tibias were not 
morphologically repaired during pregnancy but had increased mineralization of osteoid. 
In swnmary, pregnancy increased intestinal calcium absorption in Vdr null mice, 
possibly through an increase in duodenal Trpv6 expression. This led to a normalizing of 
serum PTH levels, bone turnover and ultimately an increase in BMC. In conclusion, 
intestinal calcium absorption and skeletal mineralization are regulated independently of 
1,25 (OH)2D3 and the VDR during pregnancy. 
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1. Introduction 
1.1 Vitamin D 
The "sunshine vitamin", vitamin D, is required for normal calcium and bone 
metabolism. Vitamin D deficiency results in secondary hyperparathyroidism, rickets and 
osteomalacia. Vitamin D levels are also positively correlated with bone mineral density 
(BMD) (1). Moreover, supplementation with calcium and vitamin D improves BMD 
and prevents fractures in older people (2). 
The term vitamin D refers to two biologically inactive precursors, ergocalciferol 
(D2) and cholecalciferol (D3) (3). Vitamin D2 (obtained from dietary supplements) or 
vitan1in D3 (obtained from the diet or synthesized in the skin during sun exposure) must 
undergo many enzymatic conversions to become calcitriol, the active form of vitamin D 
(1 ,25 dihydroxyvitamin D or 1 ,25(0H)2D3) . D2 and D3 become bound by serum vitan1in 
D binding proteins and enter the circulation. They are then convetied to the pro-
hormone, 25 hydroxyvitamin D (25(0H)D) by cytochrome P450 enzymes that are 
primarily located in the liver and released back into the blood stream (3). This is the 
form that is measured clinically because it is the most reliable indicator of vitan1in D 
levels ( 4). 25(0H)D is converted to 1,25(0H)2D3 by the 1 ,a hydroxylase enzyme, 
located in the kidney (3) and many other target tissues. The expression of the renal 
enzyme is stimulated by parathyroid hormone (PTH), a peptide hormone that is produced 
by the parathyroids which has an important role in regulating calcium metabolism. 
The importance of 1,25(0H)2D3 and the VDR in the regulation of calcium and 
bone metabolism is well known. Its role in regulating calcium and bone metabolism 
during the reproductive periods, however, is controversial. Here I use a mouse model to 
investigate the importance of 1 ,25(0H)2D3 and the VDR on calcium and bone 
metabolism during pregnancy. 
1.2 Calcium and bone metabolism 
1.2.1 Calcium distribution 
The adult human contains approximately 1000 grams of calciw11, of which ~99% 
exists as hydroxyapatite in the mineralized portion of the skeleton. The final 1% of the 
body's calcium exists in the blood (or serum), extracellular fluid and soft tissues. In the 
serwn, approximately 45% of total serum calcium is bound to proteins such as albumin, 
10% is complexed to anions such as citrate or phosphate. The final 45% is ionized 
calcium, which is the physiologically active portion (5). 
1.2.2 The physiological importance of calcium 
The blood provides ionized calcium for many cellular processes, including 
neuronal excitability, skeletal and cardiac muscle contraction, and bone formation. 
Calcium also serves as a signal transducer. It activates pathways that are involved in 
hormone secretion, neurotransmission, and kinase phosphorylation. Calcium 
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insufficiency disrupts these vital physiological processes and can lead to muscle cramps, 
tetany, seizures and fatal arrythmias (6). 
Maintenance of skeletal calcitm1 is also important. Flat bones, such as ribs and 
the skull, support and protect vital organs. Long bones, such as the femur and htm1orus, 
serve as levers for the muscles and support locomotion and movement. 
1.2.3 Calcium homeostasis 
To meet the needs of biochemical processes and skeletal mineral requirements, 
the amount of calcium in the blood and in the skeleton is tightly regulated. Normally in 
humans, total sertm1 calcium is maintained between 2.1 - 2.5 mM and ionized calcium 
between 1.1-1.3 mM (7). Presuming that calcitm1 intake is adequate, calcitm1 balance is 
achieved through the coordinated actions of the intestine, bone and kidney. Adults 
ingesting 1 gram of calcium per day, typically absorb only 200 mg in the small intestine 
and egest 800mg in the feces. The skeleton, which contains 1 kg of calcium, acts as a 
nearly inexhaustible calcium storage site and there is a constant exchange of calcitm1 
between the bone and the extracellular fluid. The skeleton will release about 500 mg of 
calciw11 into the blood daily due to resorption and also deposit 500mg during bone 
formation. The kidneys typically filter 10 g of calcium out of the blood per day but 
reabsorb almost 100% of this calcium back into the circulation. As a result, only 200mg 
of calcium is lost in the urine daily (5). 
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Calcium absorption in the intestine, excretion by the kidneys and exchange 
between the blood and bone is, in part, maintained through the action of the calcium 
sensing receptor (CaSR). The CaSR is a G-protein coupled receptor that is most 
prominently expressed on the surface of the chief cells of the parathyroid gland (8) and to 
a Jesser extent on segments of the nephron in the kidney. This receptor contains multiple 
Ca2+ binding elements in its extracellular domain and signaling determinants in its 
cytoplasmic region (7). The CaSR detects changes in extracellular calcium and mediates 
the minute to minute secretion of PTH. When there is a decrease in the extracellular 
calcium concentration, less calcium binds to the CaSR. As a result, the CaSR is less 
activated, releasing its inhibition on PTH synthesis and release by the parathyroid gland 
(7). 
PTH acts to increase extracellular calcium levels in three ways. Within minutes, 
PTH acts on the kidneys, to enhance calcium's return to the blood (9). In minutes to 
hours, PTH increases bone resorption, liberating calcium into the blood. PTH also 
indirectly increases intestinal calcium absorption by stimulating an increase in the renal 
synthesis of 1 ,25(0H)2D3 (1 0). All three actions help restore normocalcemia, which in 
turn, inhibits further production of PTH and 1 ,25(0H)2D3 . Certain disorders in the 
intestine, kidneys or bone may interfere with this homeostatic process (11). In these 
cases, PTH levels remain elevated (secondary hyperparathyroidism) (11 ). 
Conversely, an increase in serum calcium activates the CaSR, which suppresses 
the release of PTH by the parathyroid gland. As a result, the renal synthesis of 
1,25(0H)2D3 also decreases. Decreased PTH and 1 ,25(0H)2D3 levels result in decreased 
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bone resorption and intestinal calcium absorption. An increase in serum calcium level is 
also detected by the renal CaSR, which stimulates an increase in calcium excretion by the 
kidney, thus removing excess calcium from the circulation, returning serum calcium to 
normal levels (5). 
1.2.3.1 Intestinal calcium absorption 
Absorption of dietary calcium occurs chiefly (90%) in the small intestine (5). 
Calcium intake is typically lOOOmg daily but only 20 to 60% of dietary calcium is 
absorbed (5). The efficiency of absorption is influenced by age, calcium intake, vitamin 
D status, the state ofthe calcium homeostatic system and the bioavailability of calcium in 
the diet (12). 
Calcium is absorbed in the small intestine by two different processes, active 
transcellular transport and passive paracellular diffusion (Figure 1. 1). During adulthood 
or when calcium intake is low, active transcellular transport of calcium is high in the 
duodenum (13) which normally accounts for 10-15% absorption of the dietary load. 
Transcellular absorption of calcium involves the movement of calcium directly through 
the mucosal cells of the intestinal epithelial layer. Differences in calcium concentrations 
of the intestinal lumen (1o-3M) and the cytosol of the mucosal cell (1o-6M) create a 1000-
fold chemical and electrical gradient across the plasma membrane. This favors calcium 
entry into the cell via a transmembrane calcium ion channel, transient receptor potential, 
vanilloid type 6 (TRPV6), which is located on the apical membrane (14-16). When 
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- -------- -----------
INTESTINAL 
LUMEN BLOOD 
Figure 1.1 Active transcellular and passive paracellular intestinal calcium 
absorption. Active absorption involves the movement of calcium ions across the 
mucosal cell via a calcium ion channel (TRPV6), a calcium binding protein (calbindin-
D9K) and an energy dependent, high affinity, limited capacity Ca2+ A T Pase. Passive 
diffusion, a process driven by transepithelial electrochemical gradients, involves the 
movement of calcium ions between the membranes of adjacent intestinal mucosal cells 
and into the extracellular fluid . 
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calcium enters the cytoplasm it becomes bound by calbindin-D9K, a calcium binding 
protein (16, 17), which is sequestered in vesicles (9). Calbindin-D9K transports calcium 
ions from the apical membrane to the basolateral membrane of the absorptive enterocyte. 
The vesicles then fuse with the basolateral membrane (9). Calcium is extruded out of the 
cell and into the blood via an energy dependent, high affinity, limited capacity 
Ca2+ ATPase (9). A low affinity, high capacity sodium-calcium exchanger may play a 
minor role in transporting calcium out of the intestinal cell (18). 
I ,25(0H)2D3 is a key regulator of transcellular calcium transport. The steroid 
hormone diffuses out of the blood, across the basolateral membrane and into the musosal 
cell. It forms a complex with the nuclear VDR, a ligand dependent transcription factor 
(19). This initiates the transcription of Trpv6, calbindin-D9K (encoded by the gene 
SgJOO) and Ca2+ATPase (encoded by the gene Pmcalb), thus stimulating all three 
components involved in the active absorption of calcium across the intestine (20-23). 
PTH regulates transcellular calcium absorption indirectly. It stimulates 1-a. 
hydroxylase in the kidney to convert circulating 25-hydroxyvitanlin D to I ,25 
dihydroxyvitamin D3. Tllis increases serum 1 ,25(0H)2D3 levels, which leads to increased 
intestinal calcium absorption. 
Other hormones have been shown to stimulate intestinal calcium absorption. 
Prolactin, a hormone that stimulates mammary milk production and estrogen, the primary 
female sex hormone, may interact with their receptors to induce Trpv6 expression and 
stimulate transcellular calcium transport independently of 1 ,25(0H)2D3 (24-26). 
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Calcium also crosses the intestinal epithelium via passive diffusion. Passive 
diffusion involves the movement of calcium ions between the membranes of adjacent 
intestinal mucosal cells and into the extracellular fluid. This process is driven by 
transepithelial electrochemical gradients. The higher the concentration of calcium in the 
lumen of the intestine, the greater the diffusion of calcium between the mucosal cells. 
Paracellular calcium absorption can be regulated through the manipulation of tight 
junction proteins which control epithelial permeability (27). I ,25(0H)2D3 stimulates 
paracellular calcium absorption (28-30) through either VDR-dependent mechanisms, by 
increasing in the expression of the claudin family of tight junction proteins (30) or non-
genomic mechanisms, by stimulating signaling pathways (29). Prolactin increases 
passive calcium absorption (31, 32) possibly tlu·ough the activation of the Rho-associated 
coiled-coil forming kinase (ROCK) signaling pathway (33, 34). Lactose, a component of 
milk, has also been shown to increase intestinal calcium absorption (35). The mechanism 
of how this occurs is unknown but its degradation to glucose and galactose is involved 
(36). 
The importance of paracellular absorption has been debated. Several studies 
indicate that when calcium intake is normal or high, calcium is primarily absorbed by 
passive mechanisms in the ileum or jejunum (12, 37, 38). Conversely, a review by 
McCormick (39) suggests that the passive diffusion is not the major mechanism by which 
calcium is absorbed in normal adult humans. 
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1.2.3.2 Renal calcium excretion 
The kidney plays a central role in maintaining calcium balance. Calcium is 
filtered out of the blood in the capillaries of the glomerulus. Approximately 85% of 
filtered calcium is passively reabsorbed in the proximal tubule and the thick ascending 
loop of Henle. 15% of filtered calcium is actively reabsorbed in the distal convoluted 
tubule (5). This portion of calcium reabsorption is regulated by PTH. When there is a 
decrease in serum calcium levels, PTH binds to the PTH receptor (PTHR) on the kidney 
tubules and stimulates calcium reabsorption ( 40). As a result, less calcium is excreted in 
the urine. An increase in serum calcium activates the renal CaSR, which stimulates an 
increase in calcium excretion by the kidney, thus normalizing serum calcium (5). 
1.2.3.3 Tlze skeleton 
In addition to support and locomotion, the skeleton also acts as a storage si te for 
calcium and plays an important role in the maintenance of extracellular calcium balance. 
This is achieved through the process of bone remodeling. Bone remodeling is a complex 
coordination of cellular events that ultimately results in the formation of new bone 
through two processes, bone breakdown or resorption and bone formation or 
mineralization. Bone remodeling occurs in small packets of cells which are referred to as 
bone remodeling units ( 41 ). The skeleton is composed mainly of two bone types: dense 
cortical bone and spongy, metabolically active trabecular bone. Bone remodeling is more 
active near the marrow cavity, on the surface of trabecular bone and occurs in cycles 
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( 42). When calcium demand is high, the activation of new remodeling units may be 
required ( 41 ). This increases the number of bone resorption sites and liberates more 
calcium into the blood. Conversely, when calcium intake is high, excess calcium is 
stored in the bone tlu·ough the process of bone formation. These processes do not occur 
randomly. They are regulated by a variety of systemic hormones and local cytokines that 
act on bone forming cells or osteoblasts and bone resorbing cells, or osteoclasts. A 
complete remodeling cycle will take 3-6 months ( 43). Rates of remodeling may also 
differ depending on the location of the bone, age and activities. Bone resorption and 
formation rates are not always equal and may result in a net change in the total amount of 
BMC in the skeleton. When formation dominates over resorption, such as during 
childhood, there will be a net increase in BMC. When bone resorption dominates over 
bone formation, as it does in late adulthood, there will be a net decrease in BMC. 
1.2.3.3.1 Bone remodeling-activation 
Bone is broken down by bone resorbing cells called osteoclasts. These cells 
originate from macro phages in the bone marrow ( 44). Two cytokines are 
essential for the initiation of osteoclastogenesis; receptor activator of nuclear factor-Kf3 
ligand (RANKL) (45) and macrophage colony stimulating factor (46). RANKL, a 
member of the Tumor Necrosis Factor superfamily, is a key cytokine required for 
osteoclastogenesis. Osteoblasts, or bone forming cells, stimulate the differentiation of 
osteoclast precursors when RANKL is expressed on their surface. RANKL binds to the 
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receptor activated nuclear factor (RANK) receptor on the surface of pre-osteoclasts and 
stimulates their differentiation. Several activated pre-osteoclasts fuse to form a mature, 
multinucleated osteoclast. RANKL also stimulates mature osteoclasts to resorb bone. 
Activation of bone remodeling is negatively regulated by a local cytokine, 
osteoprotegerin (OPG). OPG is secreted by the osteoblast and binds to RANKL, thus 
preventing RANK-RANKL interactions (47, 48). This inhibits the formation of new 
osteoclasts and the initiation of bone resorption. 
Continuous administration of PTH leads to bone loss in humans. PTH binds to 
the PTHR on pre-osteoblasts and induces RANKL expression. As a result, OPG 
expression decreases, which encourages the proliferation and differentiation of pre-
osteoclasts, and the stimulation of bone resorption ( 49). 
Despite its pharmacological use to increase BMC, 1 ,25(0H)2D3 stimulates bone 
resorption (50, 51). When present at supraphysiologicallevels, 1 ,25(0H)2D3 increases 
mesenchymal cell transcription of the RANKL gene and decreases transcription of OPG 
(48). 
1.2.3.3.2 Bone remodeling-resorption 
The activated osteoclast migrates to bone and attaches to it. avP3 is the principle 
integrin mediating the attachment of osteoclasts to bone (52). This integrin recognizes 
the Arg-Gly-Asp amino acid motif which is present in many bone matrix proteins, such 
as osteopontin and bone sialoprotein. Contact with the bone surface induces the 
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formation of the sealing zone, which is caused by the rearrangement of the cytoskeleton 
to form the "actin ring". This enables the osteoclast to form an isolated 
microenvironment between itself and the underlying bone matrix. Vesicles containing 
cathepsin K, tartrate-resistent acid phosphatase and matrix metalloproteases are then 
transported to and fused with the plasma membrane that is adjacent to the bone (53). 
This results in the formation of the "ruffled border", a villus structure that is unique to 
osteoclasts. The ruffled border contains a proton pump and a Cr channel that together 
acidify the isolated resorptive compartment to a pH of ~4.5 (54). This acidic 
environment removes the mineral from the bone. The exposed bone matrix, composed 
mainly of type I collagen, is then degraded by the lysosomal enzyme, cathepsin K. The 
resulting protein fragments are endocytosed by the osteoclast and discharged from the 
opposite basal surface into the extracellular enviro1m1ent (55). The presence of degraded 
protein fragments in the serun1 (C-telopeptide), or in the urine (deoxypyridinoline (DPD)) 
are often used as biomarkers to determine the physiological rate of bone resorption. 
1.2.3.3.3 Bone remodeling-reversal 
During the intermediate phase between resorption and formation, uncharacterized 
macrophage-like mononuclear cells form a cement line over the resorption site. Tllis line 
marks the limit of resorption and helps to bind the new bone to the old bone. A spectrum 
of signaling proteins accumulate in the extracellular matrix which play key roles in the 
commitment and differentiation of mesenchymal stem cells in the bone marrow to 
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become osteoblasts (56). Pre-osteoblasts are recruited to the site to begin the bone 
formation stage. The signals that recruit osteoblasts have not been identified but it is 
likely that transforming growth factor beta, insulin growth factor I and II, bone 
morphogenic proteins, platelet derived growth factor and fibroblast growth factor may be 
involved (57-59). 
1.2.3.3.4 Bone remodeling-formation 
Upon arrival at the remodeling site, osteoblasts synthesize and secrete the organic 
matrix, composed mostly of collagen I. During this process, other proteins secreted by 
the osteoblasts, such as osteocalcin and alkaline phosphatase, will ' leak' into the 
circulation and are often used as serum biomarkers of bone formation. After the matrix is 
secreted, the osteoblasts release small membrane bound 'matrix vesicles ' that contain 
highly concentrated calcium and phosphate and other factors which create optimal 
conditions for bone mineralization ( 41 ). Osteocalcin has a high binding affinity for 
calcium. When sufficient calcium is available, it binds to the osteocalcin resulting in the 
mineralization of the matrix. Osteoblasts eventually become entombed in the mineralized 
matrix as osteocytes but maintain communication with other osteocytes by extending 
their cytoplasm through tunnel-like canaliculae (41). When calciwn is not readily 
available, the osteoid may remain unrnineralized or mineralization may be prolonged. 
1 ,25(0H)2D3 may play a direct role in the regulation of bone formation. Oral 
supplementation with vitamin D3 decreases rates of bone loss in older adult humans (60). 
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Higher serum 1,25(0HhD3levels have been associated with a higher BMD of the hip (1). 
1 ,25(0H)2D3 also enhances the synthesis of osteocalcin by osteoblasts ( 42), promotes 
exocytosis of bone materials and increases osteoblast survival (61). Furthermore, this is 
suppported by the fact that the Vdr is expressed in osteoblasts (62). Other findings 
suggest that the anabolic actions of 1 ,25(0H)2D3 are indirect, resulting from the 
suppression of PTH (63) and the stimulation of intestinal calcium absorption, which both 
encourage bone formation. 
PTH has also been used as a pharmacological stimulator of bone formation ( 64 ). 
The administration of short pulses of PTH activates the PTHR and stimulates the 
proliferation, differentiation and activation of osteoblasts, leading to an increase in bone 
formation. 
1.2.4 Adaptations during pregnancy 
During human pregnancy, the mineralizing fetal skeleton will require 
approximately 30g of calcium, 80% of this during the third trimester. This imposes a 
high demand for calcium on the maternal circulation. The mother primarily adapts to this 
demand through a doubling in intestinal calcium absorption (65, 66). Total circulating 
1 ,25(0H)2D3 is doubled early in pregnancy but free 1 ,2S(OH)2D3 levels are not increased 
until the third trimester (67). The increase in 1,25(0H)2D3 may mediate an increase in 
TRPV6, calbindin-D9K and Ca2+ ATPase, resulting in an increase in intestinal calcium 
absorption during pregnancy. There is evidence to suggest, however, that the increase in 
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intestinal calcium absorption can occur independently of 1,25(0H)2D3. The doubling in 
intestinal calcium absorption precedes the rise in free 1 ,25(0H)zD3 levels in humans and 
other man1mals (67). Also, intestinal calcium absorption was increased in vitamin D 
deficient rats during pregnancy (68, 69). Studies by Takeuchi et al. (70) suggest that 
placental lactogen, a hormone that is produced by the placenta, may stimulate intestinal 
calcium absorption. 
Studies in our laboratory in normal mice found that the mother may experience 
increases in BMC during pregnancy (71 , 72). This suggests that BMC may increase 
during pregnancy in preparation for the large skeletal losses that occur during lactation. 
Evidence in hwnans suggests that there is a small decrease in BMD by the end of 
pregnancy due to small increases in bone resorption (73, 74). These human studies are 
limited for many reasons. For example, due to concerns of fetal radiation exposure, 
BMD scans have been done months before a planned pregnancy and 1-6 weeks after, but 
not during pregnancy. Many studies lack baseline measurements and therefore the 
controls that are needed to properly interpret data. Serum and urine biomarker studies are 
also not reliable during pregnancy because of different factors such as hemodilution and 
increased glomerular filtration rate in the kidney (67) . 
1.2.5 Adaptations during lactation 
During lactation, hwnans secrete between 0.2-0.Sg of calciwn in the breast milk 
daily. This greatly increases the physiological demand for calcium in the lactating 
15 
woman. In contrast to pregnancy, lactating mothers maintain calcium balance by rapidly 
demineralizing their skeletons. Women who lactate exclusively for three to six months 
lose 5-10% bone mineral content. Female mice normally lose 25-30% ofBMD during 
three weeks of lactation. The amount of BMD lost during lactation is proportional to the 
amount of calcium lost in the milk (75). 
The mechanism by which skeletal resorption is regulated is only partially 
understood. PTH levels are reduced 50% or more during the first few months of 
lactation, suggesting that skeletal demineralization is not regulated by mechanisms found 
in non-pregnant, non-lactating females (67). There is evidence that the effects of high 
levels of parathyroid hormone related protein (PTHrP) and low estradiol levels combine 
to elevate bone resorption during lactation. PTHrP is produced by the breast during 
lactation. Its levels are elevated in the serum of lactating women and are 10,000 times 
higher in the breast milk. Studies by VanHouten et al. (76) have shown that mice lacking 
mammary PTHrP expression during lactation, lost less BMC during this time. This 
suggests that PTHrP produced by mammary tissue drives bone resorption during this 
time. Suckling and high prolactin levels suppress gonadotropins, which in turn, reduces 
the production of estradial by the ovary (67). Estradiol deficiency is well known to 
stimulate bone resorption in humans and rodents. For exan1ple, postmenopausal women 
have losses of 1.4%/year at the hip and 1.6%/year at the spine (77). Also, six months of 
estrogen deficiency induced by gonadotropin releasing hormone agonist therapy leads 
to 1-4% losses in trabecular bone mineral density (73). Although the above findings are 
consistent with a role for estrogen deficiency in bone resorption, this alone cannot 
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account for the 5-10% losses that occur in women dming lactation. It is likely that 
PTHrP and low estradiol levels act together to achieve this degree of bone resorption. 
1.2.6 Skeletal recovery after weaning 
After weaning, the maternal skeletal mineral content is rapidly and completely 
regained (73, 78, 79). During post weaning recovery, women will experience increases 
of 0.5-2% BMC per month. This is unique because BMC losses experienced as an adult 
are normally followed by a slow and incomplete recovery, as opposed to the rapid 
recovery observed post-weaning. One study by Halloran et al. (80) suggests that 
1,25(0H)2D3 may play a role. They reported that vitan1in D-deficient rats replaced some 
mineral after lactation but failed to recover to baseline. Further understanding the 
mechanism of rapid increase in bone mineral content after lactation may prove useful in 
the development of new strategies to increase BMC and treat conditions such as 
osteoporosis in the future. 
1.2. 7 Vdr knockout mouse model 
As there is no ' 1 ,25(0H)2D3 gene', several strategies have been used to study the 
absence of 1 ,25(0H)2D3 in vivo. Rats have been rendered vitan1in D deficient when 
raised in darkness and fed a diet lacking vitamin D (69, 81 , 82). The 1-a hydroxylase 
gene has been ablated in mice so that they are unable to enzymatically produce 
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1 ,25(0H)2D3, the form of vitamin D with the highest amount of physiological activity 
(83). Vdr knockout mouse models have been created independently by scientists in 
Boston (84), Leuwen (20) and Tokyo (85). In these models, the mice lack the receptor 
that is required for 1,25(0H)2D3 function. 
For my experiments, I used the Vdr knockout mouse that was created in the 
laboratory of Marie Demay at Boston. A 5kb fragment of DNA encoding the second zinc 
finger of the receptor DNA-binding domain was deleted and replaced with a neomycin 
cassette to generate Vdr null mice (84). Without a functional DNA-binding domain, the 
VDR cannot bind to DNA and is therefore unable to activate vitan1in D-dependent 
transcription. As a result, Vdr null mice have high serum 1,25(0H)2D3 levels but cannot 
utilize it. 
Vdr mice provide an animal model of the human condition, vitamin D-dependent 
rickets type II. Similar to humans, these mice are born phenotypically normal but 
develop alopecia, hypocalcemia, secondary hyperparathyroidism, rickets and 
osteomalacia by adulthood (84). This data is consistent with other Vdr knockouts (85). 
Fertility and litter sizes are also reduced in Vdr null mice (86). The phenotype, excluding 
alopecia, is a consequence of the absence ofthe Vdr in the intestine (87). Kollenkirchen 
eta!. (88) formulated an enriched diet, high in calcium, phosphorus and lactose which 
achieved normocalcemia, without raising PTH levels, in vitamin D deficient rats. When 
V dr null mice are fed this diet immediately after weaning from the mother, the 
hypocalcemia, hypophosphatemia, secondary hyperparathyroidism and skeletal 
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abnormalities are prevented (87, 89). The mechanism of how this occurs has not been 
determined but it is thought that the lactose enhances passive absorption of calcium. 
The fact that Vdr null mice do not develop abnormalities in mineral metabolism 
until post-weaning is not unexpected. In rats, during gestation and in the neonate, 
calcium absorption in the intestine occurs primarily by passive mechanisms (90). After 
18 days of age, these passive mechanisms become Jess important and are replaced by 
active, 1,25(0H)2D3-dependent absorptive mechanisms. Without the Vdr, active 
mechanisms are impaired and calcium absorption is reduced in the adult, resulting in 
severe consequences on calcium metabolism. This would explain why V dr nulls, despite 
genetic ablations, are born phenotypically normal but develop abnormalities in calcium 
homeostasis as they mature. 
1.2.8 Project description 
1 ,25(0H)2D3 and the VDR play an important role in regulating calcium 
homeostasis. Without 1 ,2S(OH)2D3 and the VDR intestinal calcium absorption is 
reduced, calcium homeostasis is impaired and the skeleton is stripped of mineral. 
Pregnancy and lactation create a large change in calcium homeostasis. Studies have 
indicated that the 1,25(0H)2D3 and the VDR may be less important in regulating calcium 
metabolism during the reproductive periods (68-70). I wanted to determine the role of 
1,25(0H)2D3 and the VDR in regulating calcium and bone metabolism during pregnancy. 
To accomplish this, I analysed the Boston Vdr knockout mouse model during this period 
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and I hypothesized that intestinal calcium absorption and calciw11 and bone homeostasis 
are regulated independently of 1,25(0H)2DJ and the VDR during pregnancy. 
For my Master's project, I first determined the consequences of pregnancy and 
lactation on skeletal mineral content. From there, I focused on how pregnancy affected 
calciwn absorption and gene expression in the duodenwn, calcium homeostasis and 
skeletal morphology in Vdr null mice. 
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2. Methods 
2.1 Anima/husbandry 
All studies were approved by the Institutional Animal Care Committee at 
Memorial University ofNewfoundland. The animals were maintained in facilities 
operated by Animal Care services of Memorial University ofNewfoundland, in 
accordance with the guidelines of the Canadian Council on Animal Care. The original 
heterozygous mice were initially backcrossed for 3 generations with normal Black Swiss 
mice and periodically thereafter, such that they were at least six generations in Black 
Swiss prior to the beginning of these experiments. Vdr heterozygous males and females 
were mated to produce heterozygous, homozygous (Vdr null) and wild-type (WT) 
offspring. 
2.2 Experimental design 
WT and V dr null females were weaned at 21 days, genotyped and raised on a 
regular (1% calcium) laboratory mouse diet for 10 weeks after which time the nulls fully 
developed hypocalcemia, secondary hyperparathryroidism and rickets. Both genotypes 
were then switched to a 2% calcium, 1.25% phosphorus and 10% lactose enriched diet 
for the remainder of the experiment. Studies by Johnson et al. (91) have shown that Vdr 
null fertility was restored to WT levels when fed a high calcium diet. Other than 
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improving fertility, it was not known how this diet would affect the mice in my 
experiments since they were not receiving the enriched diet until ten weeks of age. 
After at least one week on the enriched diet, baseline BMC measurements, whole 
blood (ionized calcium), serum, mine, duodenal (for microarray) and bone (for 
histomorphometry) samples were obtained. The mice were then mated overnight. The 
presence of a vaginal plug in the morning was designated as gestation day 0.5 of 
pregnancy. Serial BMC measmements were obtained at late pregnancy (gestation day 
18.5), late lactation (lactation day 21) and post-weaning recovery (recovery day 21). 
Serum and mine were further collected during early (gestation day 7) and late (gestation 
day 18.5) pregnancy. Duodenal samples for microarray analysis and tibias for 
histomorphometry were collected at gestation day 16.5 in order to analyze the 
molecular/cellular events that lead to the phenotype at the end of pregnancy. 
Experiments involving non-pregnant mice differed slightly. Baseline BMC and 
ionized calcium measurements were obtained while the non-pregnant Vdr nulls were 
receiving the regular 1% calcium diet. The mice were then switched to the enriched diet 
and serial BMC and ionized calcium measurements were obtained at 12 14, 20 and 22 
weeks of age. 
Results are displayed as mean ± the standard error as determined using analysis of 
variance followed by Tukey's Test. 
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2.3 Genotyping 
2.3.1 Tagging and tailing 
Mice were exposed to isoflurane (Baxter corporation) for approximately 8 
seconds after which time they were anaesthetized for approximately 5-8 seconds. An ear 
tag containing an ID number was implanted in each animal ' s right ear. Approximately 
0.5 em of tail was removed using a razor blade, placed in 0.5 ml of lysis buffer (1 OOmM 
Tris (pH 8.0), 5mM EDT A (pH 8.0), 0.2% SDS, 200mM NaCl) and incubated at 55°C 
overnight. 
2.3.2 DNA extraction from tail samples 
After the overnight incubation in lysis buffer, the tail sample was centrifuged at 
18,300 x g for 10 minutes to pellet the hair. The sample was then decanted into 0.5 ml of 
2-propanol (HPLC grade, Fisher Scientific) and inverted 5 to 10 times to precipitate the 
DNA. The precipitate was removed with a pipette tip, placed in a clean 1.5 ml centrifuge 
tube containing 0.5 ml of deionized water and hand shaken for 5 minutes to dissolve the 
DNA. 0.5 ml ofphenol: chloroform: isoan1yl alcohol (25:24:1) pH 6.7 (Fisher Scientific) 
was added, the sample was shaken by hand for 1 minute and centrifuged at 18,300 x g for 
2 minutes. The aqueous layer was removed, placed in a clean 1.5 ml centrifuge tube and 
I ml of 0.12M sodium acetate (Fisher Scientific) in reagent alcohol (Histological grade, 
Fisher Scientific) was added. This was then inverted 5 to 10 times to precipitate the 
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DNA and centrifuged for 10 minutes at 18,300 x g. The sodium acetate solution was 
decanted and 1 ml of 70% ethanol was added to wash the pellet. The sample was shaken 
by hand for approximately 10 seconds and again centrifuged at 18,300 x g for 10 
minutes. The solution was decanted and the remaining ethanol was discarded. The 
pellet was air dried for 5 to 10 minutes and resuspended in 200 J.ll T (1 OmM Tris 1 mM 
EDT A, pH 8.0). 
2.3.3 Polymerase chain reaction (PCR) 
A --450bp region of exon 3 of the WT Vdr gene and a 308bp region of the 
neomycin gene were amplified by PCR using two primer sets. The primers used to 
amplify the WT product were as follows: forward primer: 5' -CTG CCC TGC TCC ACA 
GTC CTT-3', reverse primer: 5' -GCA GAC TCT CCA ATG TGA AGC-3 ' . The primers 
used to amplify the neomycin cassette are as follows: forward primer: 5' -GGA GAG 
GCT ATT CGG CTA TGA C-3 ', reverse primer: 5' -CGC ATT CGA TCA GCC ATG 
ATG G-3 ' . 1 f.ll of genomic DNA was added to 49f.ll of a PCR cocktail containing 1 X 
PCR Buffer (20mM Tris-HCl (pH 8.4), 50mM KCI), 2mM MgCl, 0.2mM 
deoxynucleotide triphosphates (dNTPs), I U Taq DNA polymerase) in a 0.6 ml thin 
walled PCR tube (Fisher Scientific). For each experiment, DNA was omitted from one 
tube to serve as a negative control. The samples were then loaded into a Peltier Thermal 
Cycler (MJ Research). The PCR program included the followed conditions: denaturation 
at 94°C for 4 minutes, 35 cycles of denaturation at 94°C for 1 minute, annealing at 62°C 
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for 1 minute, polymerization at 72°C for 1 minute. After these 35 cycles, the program 
was completed with a 7 minute polymerization at 72°C. The PCR products were stored 
at 4 oc until gel electrophoresis was performed. 
2.3.4 Gel electrophoresis 
PCR products were separated by gel electrophoresis. Agarose (1.2g) (Invitrogen) 
was added to 100 ml of buffer (0.4M Tris, 20mM EDT A, 1.14% Acetic Acid, pH 8.5) in 
a 500ml Fleak:er and boiled in the microwave. The solution was cooled slightly and 20 
111 of SYBR Safe DNA gel stain (Invitrogen) was added. The solution was mixed 
gently and poured into a gel electrophoresis chamber (Easy Cast) containing a loading 
well comb. The solution was cooled for 20 minutes during which time it solidified to 
form a gel. Orange G loading dye (5 J .. d) was added to the 50!11 PCR sample and mixed. 
The PCR sample/orange G mixture (10!11) was loaded into each well. The PCR product 
ran on the gel for 30 minutes at 200 volts. A digital picture of the gel was taken using a 
Gel Logic 100 Imaging system (Mandel Scientific). 
2.4 Bone mineral content 
WT and Vdr null mice were switched from the enriched 2% calcium diet to a 
regular 1% calcium diet 18 hours prior to scanning for BMC. In advance of the scan, 
each mouse was anaesthetized (40!11 of83.3mg/ml Ketan1ine, 3.3 mg/ml xylazine, i.p.). 
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After at least one week on the enriched diet, baseline total (whole body, excluding the 
head) BMC was measured using a Lw1ar Piximus2 bone densitometer (General Electric). 
Regional measurements (spine and hindlimb), were derived from the whole body scans. 
The mice were then mated and pregnancies were achieved within 0-12 weeks. Additional 
BMC measurements were obtained during early pregnancy (gestation day 7), late 
pregnancy (gestation day 18.5), early lactation (lactation day 7), late lactation (lactation 
day 21) and recovery (21 days after weaning). The results are expressed as the relative 
change in BMC from the non-pregnant baseline, which has been set to zero. The 
densitometer was calibrated daily using a Phantom quality control composed of a known 
amount of fat (11.9%) and BMC (0.063 grams). 
2.5 Intestinal 45Ca transfer 
Intestinal calcium absorption was measured using the duodenal ligated loop 
technique (adapted from Song et al, 2003). The mouse was anaesthetized using a 30J..tl 
i.p. injection (83.3 mg/ml ketamine/3.3 mg/ml xylazine). The abdomen was shaved and 
the peritoneal cavity was opened. One suture was tied arow1d the duodenwn adjacent to 
the pyloric sphincter and a second suture was placed approximately two centimetres 
distal to the first. 45Ca buffer (40Jll of 45Ca (16 J.!Ci/ml), NaCI (150mM), CaCh (2mM), 
Tris-HCl (30rnM, pH 7.2)) was injected into the lumen of the closed loop of duodenum. 
l6f-I.Ci of 45Ca was also injected into a scintillation vial to serve as a negative control. 
The mouse' s abdomen was kept warm with gauze soaked in warm phosphate buffered 
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saline (PBS) and the heartbeat was monitored. After 10 minutes, the loop was excised 
external to the sutures, placed in a scintillation vial and solubilized overnight in 5ml 
Scintigest (Fisher Scientific) at 65°C on a shaker. Loops that appeared non-viable 
(purple) or deflated were discarded. The samples were then pulse vortexed until they 
were disrupted. After scintillation fluid (1 0 ml, Fisher Scientific) was added, the vials 
were counted in a LS 6500 Multi-purpose liquid scintillation counter (Beckman Coulter). 
The results are expressed as a percentage of the initial amount of 45Ca that was injected 
into the loop. 
2.6 RNA expression analysis in the duodenum and vertebrae. 
2.6.1 Tissue collection 
At each timepoint, tissue samples were collected for RNA, protein and histology. 
Mice were killed by cervical dislocation. The tissues were dissected, snap frozen in 
liquid nitrogen and stored at -80°C. 
2.6.2 RNA extraction 
The homogenizer was cleaned between samples by rinsing with an RNA wash 
solution (2mmol EDTA, 0.1% SDS, 0.1 % Diethyl pyrocarbonate, (DEPC)(Sigma)) and 
Ribonuclease-free deionized water. 
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1m! ofTrizol reagent (Invitrogen) was added to each sample in a 14m! 
polystyrene centrifuge tube and the tissue was disrupted using a Polytron homogenizer 
(Kinematica) for 1 minute at high speed in a fwne hood. The samples were incubated at 
room temperature for 5 minutes. 
Chloroform (0.2rnl, Fisher Scientific) was added to the samples. The tubes were 
covered with Parafilm and shaken for 15 seconds. The san1ples were incubated at room 
temperature for 3 minutes and centrifuged at 12,000 x g for 15 minutes at 4°C. The RNA 
(upper aqueous layer) was transferred to a clean 1.5ml centrifuge tube. 
Isopropanol (0.5 ml, HPLC grade, Fisher Scientific) was added to precipitate the 
RNA. Each tube was mixed, incubated on ice for 10 minutes and centrifuged at 12,000 x 
g for I 0 minutes at 4 °C. The RNA pellet was washed with 80% ethanol (treated with), 
vortexed and centrifuged at 7500 x g for 5 minutes, at 4°C. The ethanol was decanted 
and the RNA pellet was air dried for 30 minutes at room temperatme. The RNA was 
resuspended in 500!!1 of RNase-free water by passing the solution through a pipette tip a 
few times. 
Impurities were removed from the RNA sample by performing RNA clean up 
using the RNeasy Midi kit (Qiagen). This resulted in a 150f-t! total RNA sample, ranging 
in concentration from 0.5-2.0f-tg/f-tl. RNA quality was determined at the Hospital for Sick 
Children (Toronto, ON) using a Bioanalyser 2100 (Agilent Teclmologies). RNA samples 
with an RNA Integrity Number (RIN)>7 were used for microarray analysis and real time 
RT-PCR. 
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2. 6.3 Whole genome microarray analysis 
WT and Vdr null total RNA samples from baseline and late pregnancy were 
analyzed at the Centre for Applied Genomics, Microarray Facility Hospital for Sick 
Children (Toronto, ON). The Mouse Gene T 1.0 Array (Affymetrix) was completed on 
8 samples ( 1 sample per chip), representing 2 san1ples for each of the 4 groups: WT and 
Vdr null at baseline (pre-pregnancy) and pregnancy (gestation day 18.5). 
Primary data analysis at the Statistical Analysis Core Facility of The Centre for 
Applied Genomics used the March 2008 gene a1111otation information fi·om Affymetrix. 
Probesets without gene names/gene assig11111ents were removed, leaving 22158 probesets. 
Raw data were normalized using the robust multi-array average (RMA) algorithm (92). 
Statistical analysis involved four comparisons ofraw data; Vdr null baseline vs. WT 
baseline, Vdr null late pregnancy vs. Vdr null baseline, WT pregnancy s. WT baseline 
and Vdr null pregnancy vs. WT pregnancy. Differentially expressed genes were then 
identified using the Local-Pooled-En-or Test (LPE) (93). False discovery rate (FDR) (94) 
was set at 0.05 such that genes with adjusted p-values < 0.1 were considered to be 
statistically significant. A p-value of 0.1 was chosen because of the small sample size. 
The genes that showed significant changes in expression among timepoints (ie. Vdr null 
pregnancy vs. Vdr null baseline) are shown in Appendix A. To identify common genes 
that were differentially expressed, I compared each statistical group comparison and 
listed the similarities and differences among common genes (Appendix B). My analysis, 
however, focused on the expression of genes that are known to be involved in the active 
transport of calcium across the duodenum (Trpv6, Sgl 00, Prncal b). 
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2.6.4 Validation ofmicroarray results using real time RT-PCR. 
Real time RT-PCR was performed on each RNA sample to validate the 
expression of Trpv6, Sgl 00 and Pmcal b mRNA as determined by microarray. eDNA 
synthesis and amplification were performed in one step using TaqMan® RNA-to-C/ M ]-
Step Kit and TaqMan® Gene Expression Assays (Applied Biosystems). A reaction 
cocktail containing approximately 12.51lg of total RNA, IX TaqMan® RT Enzyme Mix, 
IX TaqMan® RT-PCR Mix and IX TaqMan® Gene Expression Assays for either Trpv6, 
SgJOO, Pmcalb or glutaraldehyde-3-phosphate dehydrogenase (Gapdh). Each assay was 
run in triplicate, three times for each gene. The cocktail (20J.!l) was loaded onto an 
Optical 96-Well Thermal Cycling plate (Applied Biosystems). Each well was covered 
using Optical Caps (Applied Biosystems) and the plate was centrifuged at 2000 x g for 1 
minute. The plate was then transferred to an ABI 7000 Thermocycler (Applied 
Biosystems) and an absolute quantification document was selected. The RT -PCR 
program included eDNA synthesis: 48°C for 15 minutes, enzyme activation: 95°C for 10 
minutes and 40 cycles of denaturing: 95°C for 15 seconds and annealing/extension: 60°C 
for 1 minute. The resulting amplification curves were used to determine the threshold 
cycle (CT) values for each sample. The data for each gene was normalized to the 
' housekeeping' gene Gapdh and expressed relative to another genotype or reproductive 
timepoint, depending on the comparison. 
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2. 7 Serum analysis 
The tail was nicked using a razor blade, whole blood was collected into a 
capillary tube and then transferred into a 1.5 ml polypropylene centrifuge tube. The 
blood was incubated at room temperature for 30 minutes and then centrifuged for 10 
minutes at 15,800 x g. The clear serum layer was removed with a pipette, placed in a 
fresh 0.6ml centrifuge and stored at -80°C. Prior to each assay performed on the sample, 
the san1ple was thawed and centrifuged for 10 minutes at 15,800 x g. 
2. 7.1 Serum ionized calcium 
Serum ionized calcium (Ca2+) was determined using the 634 Ca2+/ pH analyzer 
(Chiron Diagnostics). Whole tail blood samples were collected in a 60f..tl capillary tube 
(Bayer) and capped with an adaptor. The blood sample was immediately loaded in to the 
machine and the ionized calcium results (corrected for pH 7.4) were obtained. 
2. 7.2 Serum PTH 
Serum PTH was measured using a rat intact PTH enzyme linked immunosorbet 
assay (ELISA) kit (Immutopics, Inc). This kit is cross-reactive to mouse PTH. 25fll of 
undiluted serum, standards and controls were loaded into a streptavidin coated 96 well 
plate. Two antibodies; a biotinylated rat anti-PTH and a horseradish peroxidase 
conjugated rat anti-PTH, were added and incubated for three hours. As a result, the PTH 
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in the serum sample is captured and immobilized on the surface of the well and tagged 
with HRP. After five washes with a buffer, an HRP substrate was added and the 
enzymatic activity of HRP was measured by reading the absorbance at 45011m using a 
kinetic microplate reader (Molecular Devices). The at110w1t of HRP activity is directly 
proportional to the amount of PTH in the sample. The absorbance of each standard was 
plotted against their known concentration on a linear-linear standard cmve. This standard 
curve was used to determine the concentration of PTH in the serum san1ples. Samples 
with apparent values below the detection limit (1.6 pg/ml) were assigned values equal to 
the detection limit. 
2. 7.3 Serum osteocalcin 
Serum osteocalcin was measured using the mouse osteocalcin IRMA kit 
(Immutopics, Inc) according to the manufacturer's protocol. Serum was diluted 1:11 
with zero standard prior to the assay. A standard, control or diluted serum (25f..ll) was 
added to a 2 ml polystyrene tube. 1251 labeled anti-mouse osteocalcin antibody (200f..ll) 
was dispensed into the tubes. The tubes were mixed by vortexing on low and one bead 
coated with anti-mouse osteocalcin antibodies was added to each tube. The tubes were 
incubated at room temperature for 18-24 hours. The liquid was aspirated and the beads 
were washed three times with 0.1 M PBS. Each tube was counted in a gamma counter 
for one minute. The counts per minute (cpm) were plotted against the known 
concentration for each standard to produce a log-log standard curve. This standard curve 
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was used to determine the concentration of osteocalcin in the diluted serum samples. 
These values were then multiplied by the dilution factor. 
2.8. Urine analysis 
Mice were placed in empty sterile cages until they produced mine. The mine was 
collected, placed in a 0.6ml polypropylene centrifuge tube and stored at -20°C. Prior to 
each ofthe following assays, the urine was centrifuged at 15,800 x g for 5 minutes. 
2.8.1 Urine deoxypyridinoline (DPD) 
Urine DPD was measured using the Metra DPD Enzyme Immunoassay (EIA) 
(Quidel). Standards, controls and urine were diluted 1:10 with assay buffer. 50J.!l of each 
was added to wells coated with monoclonal anti-DPD antibody. DPD conjugated to 
alkaline phosphatase (1 OOJ.!l) was added to wells and incubated at room temperature for 2 
hours in the dark. The wells were washed three times with buffer and inverted for 5 
minutes. 150J.!l of pNPP substrate was added to the wells and incubated for 1 hour at 
room temperature. 1 OOJ.!l of stop solution was added and the absorbance at 40511m was 
obtained using a kinetic microplate reader (Molecular Devices) to determine the amount 
of alkaline phosphatase activity in each well. Due to the competitive nature of the assay, 
the an1ount of alkaline phosphatase activity was inversely proportional to the amount of 
DPD in the sample. The absorbances of the known standards were used to construct a 
33 
standard curve ( 4 parameter). This standard curve was used to determine the 
concentration of DPD in the diluted urine samples. These DPD values were then 
multiplied by the dilution factor and expressed relative to the urine creatinine 
concentration (nmol DPD/mmol creatinine) to correct for urinary concentration. 
2.8.2 Urine creatinine 
Urine creatinine was determined using the Creatinine-S spectrophotometric assay 
(Diagnostic Chemicals Limited (DCL)). Urine samples were diluted 1110 in 0.9% NaCI. 
1 OOJ.!l of creatinine standard, control (DC-Trol, DCL) or urine were added to 4ml 
cuvettes (Fisher Scientific). Creatinine working reagent (2.0ml) was added to the cuvette 
and mixed. An Ultraspec 2000 spectrophotometer (Pharmacia Biotech) was used to 
obtain the absorbance at 51 011m at 20 and 80 seconds after the reagent was added. The 
change in absorbance of the unknown urine sample relative to the change in absorbance 
of the known standard was used to calculate the concentration of the unknown. These 
values were then multiplied by the dilution factor. 
2. 8.3 Urine total calcium 
Urine total calcium was measured using a calcium spectrophotometric assay 
(Diagnostic Chemical Limited (DCL). Depending on the concentration, urine samples 
were diluted 1/2 or 1110 in 0.9% NaCI. IOJ.!l of standard, control (DC-Trol, DCL) or 
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urine and 1.0 ml of reagent were combined in a l.Oml polystyrene semi-cuvette, mixed 
and incubated at room temperature for at least 30 seconds. An Ultraspec 2000 
spectrophotometer (Pharmacia Biotech) was used to measme the absorbance of the 
solution at 65011m using water as a reagent blank. The absorbance of the known calcium 
standard was used to calculate the concentration of calcium in the serum samples. These 
values were then multiplied by the dilution factor and expressed relative to the mine 
creatinine concentration (mmol calcium/mmol creatinine) to correct for minary 
concentration. 
2. 9 Histology 
Tibias were removed, stripped of muscle and other soft tissues and fixed in 10% 
buffered formalin. The samples were embedded in methacrylate by my supervisor, Dr. 
Christopher Kovacs while on sabbatical in the laboratory of Dr. Natalie Simms in St. 
Vincent' s Institute, Melbourne, Victoria, Australia. Undecalcified 5-micron sections 
were stained with either the Goldner's trichrome and von Kossa methods or toluidine 
blue stain. 
2.9.1 Goldner's trichrome method 
Undecalcified tibia sections were deplasticized in cellosolve (Acros organics) for 
2 X 25 minutes, rehydrated in decreasing ethanol series and tap water (3 minutes each). 
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The sections were stained with Ponceau/ Acid Fuchsin/ Azophloxine for 5 minutes and 
rinsed in 1% acetic acid for 10 seconds. The sections were placed in phosphomolybdic 
acid/ Orange G for 5 minutes and rinsed in 1% acetic acid for 10 seconds. The slides 
were then stained with Light Green for 5 minutes, rinsed in 1% acetic acid for 3 minutes 
and blotted dry. The sections were passed through two changes of butanol, one 
butanol/toluene mixture, two changes of toluene, mounted with Depex and coverslipped. 
Goldner' s trichrome stains nuclei blue/black, mineralized bone/muscle green and osteoid 
red. 
2.9.2 Von Kossa method 
Undecalcified tibia sections were deplasticized in cellosolve (Acros organics) for 
2 X 25 minutes, rehydrated in decreasing ethanol series and deionized water (3 minutes 
each). The slides were then incubated in 2% silver nitrate for 30 minutes under a strong 
light and washed in deionized water for five minutes. Sodium thiosulfate (2.5%) 
followed for 5 minutes and rinsed three times in deionized water. The sections were 
counterstained with methyl green (3 minutes) and blotted. The stain was cleared with 
two passes through butanol. The sections were then mounted with Depex and 
coverslipped. Mineralized bone stains black using the Von Kassa method. 
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2.9.3 Toluidine blue stain 
Tibia sections were deplasticized in cellosolve (Acros organics) for 2 X 25 
minutes and rehydrated in decreasing ethanol series and tap water (3 minutes each). The 
sections were stained in toluidine blue for 5 minutes, dipped in two changes of toluidine 
blue buffer and blotted. The stain was cleared by passing through butanol twice, a 1: 1 
butanol/toluene solution and toluene twice. The sections were mounted with Depex and 
coverslipped. Toluidine blue stains nuclei blue, mineralized bone light purple and 
osteoid colourless to pale blue. 
2.10 Histomorpltometry 
Histomorphometric analysis of Vdr null proximal tibias (stained with toluidine 
blue) was carried out according to standard procedures using the Osteomeasure system 
(Osteometries, Decatur, GA). Due to the sinuous nature of the Vdr null growth plate the 
analyzed region began immediately below the lowest arc of the chondroosseous junction 
and extended toward the diaphysis. The parameters analyzed were as follows: Bone 
volume (BY /TV): the total bone marrow volume occupied by trabecular bone; Trabecular 
nun1ber (Tb.N): the amount of trabeculae present in the field ; Trabecular thickness 
(Tb.Th): the average thickness of the trabeculae present in the field; Trabecular spacing 
(Tb.Sp): the average distance between trabecular midpoints; Osteoblast number 
(N.Ob/BPm): the number of osteoblasts (defined as blue/grey cuboidal cells aligned in 
clusters at the bone surface) per bone perimeter; Osteoclast number (N.Oc/BPm): the 
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number of osteoclasts (defined by the standard criterion of multinucleated cells residing 
in resorptive lacunae) per bone perimeter; Osteoclast surface (OcS/BS): the amount of 
bone surface containing osteoclasts per total bone surface; Osteoid surface (OS/BS): the 
amount of osteoid surface per bone surface. 
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3. Results 
3.1 Bone mineral content 
In order to determine how the rachitic Vdr null skeleton would respond to the 
challenges of pregnancy and lactation, I first investigated the changes in total BMC in 
Vdr null and WT mice throughout the reproductive cycle. Regional measurements of the 
spine and tibia were also analysed to determine if the changes in BMC involved 
trabecular bone, cortical bone, or both. 
Relative changes in total BMC in Vdr null and WT mice throughout the 
reproductive periods are shown in Figure 3.1. WT mice gained 7.1% BMC during 
pregnancy, lost 18.1% during lactation and recovered to baseline post weaning. 
Regional measurements showed that WT mice gained 1.1% spine BMC during 
pregnancy, lost 17.7% during lactation and recovered 8.3% above baseline post-weaning 
(Figure 3. 2). WT mice also gained 12.7% hindlimb BMC during pregnancy, lost 18.3% 
during lactation and recovered post-weaning 8.3% above baseline (Figure 3. 3). In 
contrast, Vdr null sisters gained 57.2% BMC by late pregnancy (p<0.05), lost 31.2% 
during lactation and recovered post-weaning to a value that was 49.1% higher than the 
pre-pregnancy baseline (Figure 3. 1). Changes in spine BMC were even greater, with a 
61.5% (p<0.05) increase during pregnancy, a 52.8% (p<0.05) decrease during lactation 
and a recovery to 48.9% above baseline (Figure 3.2). Vdr nulls also gained 34.0% 
hindlimb BMC during pregnancy, lost 25.7% during lactation and recovered post 
weaning, 29.5% above baseline (Figure 3.3). 
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Figure 3.1 Relative changes in BMC throughout the reproductive periods in WT 
(blue) and Vdr null (red) mice. Mice were raised on a normal I% calcium diet for I 0 
weeks. They were then switched to a 2% calcium, 1.25% phosphorus and 20% lactose 
enriched diet. After at least 7 days on the enriched diet, baseline BMC measurements 
were obtained using the Lunar Piximus2 bone densitometer. The mice were then mated 
and allowed to follow through the entire reproductive cycle with additional BMC 
measurements obtained at late pregnancy, late lactation and post-weaning recovery. The 
results at each time point are displayed as the mean relative change in BMC (±SE) as 
compared to baseline measurements. 
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Figure 3.2 Relative changes in spine BMC throughout the reproductive periods in 
WT (blue) and Vdr null (red) mice. Mice were raised on a normal I% calcium diet fo r 
10 weeks. They were then switched to a 2% calcium, 1.25% phosphorus and 20% lactose 
enriched diet. After at least 7 days on the enriched diet, baseline BMC measurements 
were obtained using the Lunar Piximus2 bone densitometer. The mice were then mated 
and allowed to follow through the entire reproductive cycle with additional BMC 
measurements obtained at late pregnancy, late lactation and post-weaning recovery. The 
results at each time point are displayed as the mean relative change in spine BMC (±SE) 
as compared to baseline measurements. 
4 1 
u 
L 
co 
50 
.0 30 
E 
"'0 
c 
I 
c 20 
QJ 
Ol 
c 
ro 
..c 10 u 
QJ 
> 
:.:::; 
ro 
QJ 
cr:: 0 
-10 
Late Pregnancy 
(5) (5) (5) 
Recovery 
(5) (5) (4) 
• wT 
• vdr null 
Figure 3.3 Relative changes in hindlimb BMC throughout the reproductive periods 
in WT (blue) and Vdr null (red) mice. Mice were raised on a nonnal I% calcium diet 
for 10 weeks. They were then switched to a 2% calcium, 1.25% pho phorus and 20% 
lactose enriched diet. After at least 7 days on the enriched chow, baseline BMC 
measurements were obtained using the Lunar Piximus2 bone den itometer. The mice 
were then mated and allowed to follow through the entire reproductive cycle with 
additional BMC measurements obtained at late pregnancy, late lactation and post-
weaning recovery. The results at each time point are displayed a the mean relative 
change in hindlimb BMC (±SE) as compared to baseline measurements. 
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Absolute values of baseline total bone mineral content (BMC) in Vdr null and WT 
mice throughout the reproductive periods are shown in Figure 3. 4. At pre-pregnancy 
baseline, Vdr null sisters had a significantly reduced BMC (0.38g) as compared to their 
WT sisters (0.53g). During pregnancy and recovery from lactation, Vdr nulls increased 
their BMC significantly to equal WT levels. 
In order to separate the effect of the enriched diet from that of pregnancy on 
BMC, I assessed changes in BMC in non-pregnant V dr nulls from 10 to 22 weeks of age. 
Relative changes in total BMC in non-pregnant Vdr nulls while receiving the enriched 
chow as compared to the pre-diet baseline (10 weeks) are shown in Figure 3.5. Vdr nulls 
significantly increased BMC at 12, 14, 18 and 22 weeks of age. During the 12 weeks of 
scanning, BMC increased 58% by 22 weeks, which was equal to the amount gained 
dming pregnancy and recovery from lactation (indicated by dotted line). 
To further assess the effect of the enriched diet on BMC, I wanted to determine if 
there was a relationship between the amount of time between baseline and late pregnancy 
scans and the an1ount of BMC gained (Table 3. 1). WT mice had a mean 3 weeks on the 
enriched diet and gained only 7.1% BMC during pregnancy. Three Vdr null mice had a 
mean 3.5 weeks on the enriched diet and gained 41% BMC during that time. Two Vdr 
null mice had a mean 14 weeks on the diet and gained 71%. 
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Figure 3.4 Changes in absolute BMC in Vdr null (red) and WT (blue) mice 
throughout the reproductive periods. Mice were raised on a normal I% calcium diet 
for I 0 weeks. They were then switched to a 2% calcium, 1.25% phosphorus and 20% 
lactose enriched diet. After at least 7 days on the enriched diet, baseline bone mineral 
content measurements were obtained using the Lunar Piximus2 bone densitometer. The 
mice were then mated and allowed to follow through the entire reproductive cycle with 
additional BMC measurements obtained at late pregnancy, late lactation and post-
weaning recovery. The results are djsplayed as mean total BMC (±SE). 
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Figure 3.5 Relative change in BMC in non-pregnant Vdr null mice after receiving 
the enriched chow as compared to their pre-diet baseline (10 weeks). Mice were 
raised on a nonnal I% calcium chow for I 0 weeks. BMC measurements were obtained 
using the Lunar Piximus2 bone densitometer. They were then switched to a 2% calcium, 
1.25% phosphorus and 20% lactose enriched diet. Serial BMC measurements were 
obtained at 12, 20 and 22 weeks and expressed relative to their BMC at I 0 weeks 
(mean±SE). *statistically different from baseline. 
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Time 
between Average Relative Average 
Mouse Genotype ID# Baseline and time . . relative mcrease m 
Late (weeks) BMC (%) mcrease 
Pregnancy (%) 
scans 
(weeks) 
1 WT X723 2.5 18.1 
2 WT X765 2.5 3±0.3 6.97 7.1 ±17 
3 WT X742 4 1.18 
4 WT X 1309 3 4.91 
5 WT X1310 3 4.47 
6 Vdr null X740 2.5 28.2 
7 Vdr null X727 4 3.5 25.9 41±13 
8 Vdr null X768 4 68.9 
9 Vdr null X786 12 54.4 
10 Vdr null X769 16 14±1.2 87.3 71 ±17 
Table 3.1 The time between baseline and late pregnancy scans for each Vdr null and 
WT mouse and the amount of BMC gained. Mice were raised on a normal 1% 
calcium diet for 10 weeks. BMC measurements were obtained using the Lunar Piximus2 
bone densitometer. They were then switched to a 2% calcium, 1.25% phosphorus and 
20% lactose enriched diet and mated. An additional scan was obtained at late pregnancy 
(gestation day 18.5). The time between baseline and pregnancy scans and the increase in 
BMC are expressed as mean ±SE. 
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3.2 Duodenal 45Ca absorption 
To determine if the increased BMC was due to an increa e in calcium absorption 
that was independent of the V dr, I measured duodenal 45 Ca absorption in V dr null and 
WT mice (Figure 3. 6). These results are displayed in Figure 3. 6. At ba eline, while 
consuming the enriched diet, duodenal 45Ca absorption was reduced in Vdr nulls as 
compared to WT. In contrast, at the end of pregnancy 45Ca absorption is significantly 
increased in Vdr null mice (p<0.05) as compared to baseline. 
3.3 Duodenal gene expression 
To examine the cellular mechanisms involved in the upregulation of intestinal 
calcium absorption in Vdr null mice during pregnancy, I performed a whole genome 
microarray analysis (Mouse Gene ST 1.0, Affymetrix) of gene expression in the 
duodenum at baseline and during pregnancy. All significant relative changes in gene 
expression (p<0.1) are listed in Appendix A for each statistical comparison. Relative 
changes in genes that were common an1ong groups are listed in Appendix B. 
My analysis focused on the results for genes that were known to be involved in 
the active transport of calcium across the duodenum. The relative changes in duodenal 
Trpv6, Sgl 00 and Pmcal b mRNA expression as determined by microarray analysis are 
listed in Table 3. 2. Vdr null T1pv6 expression was reduced to 0.13 fold (p<0.005) at 
baseline as compared to WT. In contrast, T1pv6 mRNA expression 
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Figure 3.6 Duodena1 45Ca absorption in Vdr null (red) and WT (blue) mice at 
baseline and gestation day 16.5 of pregnancy. Mice were rai ed on a normal 1% 
calcium diet for I 0 weeks. They were then witched to a 2% calcium, 1.25% phosphorus 
and 20% lactose enriched diet. Duodenal 45calcium absorption was measured at either 
baseline or late pregnancy using the in situ ligated loop technique. Mice were fasted for 
approximately 18 hours before the procedure. Duodenal 45Ca ab orption is expressed as 
the amount of calci urn remaining in the loop as a percentage of the amount of 5Ca that 
was initially injected into the loop (mean±SE). 
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Comparison Trpv6 SgJOO Pmcalb 
Vdr null baseline vs. WT baseline 0.13,p<0.005 0.85 (NS) 0.69 (NS) 
V dr null pregnancy vs. baseline 4.8,p<0.005 0.98 (NS) 1.02 (NS) 
WT pregnancy vs. baseline 0.33,p<0.005 0.96 (NS) 0.78 (N ) 
V dr null pregnancy vs. WT pregnancy 1.91 ,p<0.005 0.88 (NS) 0.90 (NS) 
Table 3.2 Relative duodenal mRNA expression of Trpv6, SgJOO and Pmcalb as 
determined by whole genome microarray analysis (Affymetrix). Mice were raised on 
a normal 1% calcium chow for 10 weeks. They were then switched to a 2% calcium, 
1.25% phosphorus and 20% lactose enriched diet. Duodenal samples were collected at 
either baseline or late pregnancy (gestation day 16.5) and total RNA was extracted. 
Microarray analysis and statistical analysis were performed at The Centre for Applied 
Genomics (Hospital for Sick Children, Toronto). The results are expressed as mean 
relative mRNA expression between each comparison. 
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significantly increased 4.8 fold (P<0.005) during pregnancy as compared to baseline. 
WT Trpv6 mRNA expression decreased significantly during pregnancy as compared to 
WT baseline and pregnant Vdr nulls. Calbindin-D9K and Ca2+ ATPase expression were 
not significantly different between Vdr null or WTs at baseline or late pregnancy. 
To confirm the microarray results, I performed real time RT-PCR on the same 
Vdr null and WT baseline and late pregnancy RNA samples. The relative change in 
duodenal Trpv6, Sgl 00 and Pmcal b mRNA expression as determined using real time 
RT-PCR are shown in Table 3.3. Vdr null Trpv6 expression (Figure 3. 7) was reduced at 
baseline as compared to WT. T1pv6 mRNA expression significantly increased 13.5 fold 
during pregnancy as compared to baseline and was 3 fold higher (p<O.O 1) than pregnant 
WTs. WT Trpv6 mRNA expression was decreased significantly during pregnancy as 
compared to WT baseline and pregnant Vdr nulls. SglOO and Pmcalb expression did not 
change significantly in Vdr null or WT at baseline or late pregnancy (Table 3.3). 
3.4 Calcium homeostasis 
To determine ifthe increase in duodenal calcium absorption in Vdr null during 
pregnancy affected maternal calcium homeostasis I analyzed serum ionized calcium, 
urine calcium and parameters of secondary hyperparathyroidism (serum PTH and bone 
turnover markers). 
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Comparison Trpv6 SglOO Pmcalb 
0.04±0.00 0.57±0.03 0.34±0.02 
V dr null baseline vs. WT baseline NS NS NS 
13.5±2.37 0.70±0.08 1.0±0.07 
V dr null pregnancy vs. baseline p<O.OOl NS NS 
0.18±0.05 0.81±0.1 0.42±0.03 
WT pregnancy vs. baseline p<0.06 NS NS 
3.05±0.16 0.52±0.01 0.82±0.01 
V dr null pregnancy vs. WT pregnancy p<O.Ol NS NS 
Table 3.3 Relative duodenal mRNA expression of Trpv6, SglOO and Pmcalb as 
determined by real time RT -PCR. Mice were raised on a normal 1% calcium diet for 
10 weeks. They were then switched to a 2% calcium, 1.25% phosphorus and 20% lactose 
enriched diet. Duodenal samples were collected at either baseline or late pregnancy 
(gestation day 16.5). Duodenal total RNA was analyzed using TaqMan® RNA-to-CTTM 
1-Step Kit and TaqMan® Gene Expression Assays. The relative expression was 
calculated using the 2 -MCT method and are expressed as mean relative expression ±SE. 
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Figure 3. 7 Relative expression of duodenal Trpv6 in WT (blue) and Vdr null (red) 
mice at baseline and pregnancy as determined using real time RT-PCR. Mice were 
raised on a normal I% calcium diet for I 0 weeks. They were then switched to a 2% 
calcium, 1.25% phosphorus and 20% lactose enriched diet. Duodenal samples were 
collected at either baseline or late pregnancy (gestation day 16.5). Duodenal total RNA 
was analyzed using TaqMan® RNA-to-C/M l-Step Kit and TaqMan® Gene Expression 
Assays. The results were calculated using the 2·McT method and displayed as mean 
relative expression ±SE. 
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3.4.1 Serum ionized calcium 
Serum ionized calcium was measured to determine if the increase in duodenal 
calcium absorption in Vdr nulls during pregnancy caused serum calcium levels to 
normalize. Figure 3.8 shows the preliminary results for ionized calcium in Vdr null mice 
at baseline and late pregnancy. WT baseline mean ionized calcium is indicated by the 
dotted line (1.17mmol/L). At baseline, the Vdr null was hypocalcemic (0.68 mmol/L). 
By late pregnancy, Vdr null ionized calcium increased to WT levels. 
In order to determine the effect of the enriched diet on serum ionized calcium, I 
measured serum ionized calcium in non-pregnant Vdr nulls from 10-22 weeks of age 
(Figure 3.9). As shown, Vdr nulls were hypocalcemic while consuming both the regular 
(10 weeks) and enriched diets (12 weeks). By age 22 weeks, Vdr null ionized calcium 
significantly increased to WT levels. 
3.4.2 Urine calcium 
In order to determine if urine calcium excretion was altered in Vdr nulls during 
pregnancy, urine calcium was measured. Figure 3.10 displays urine total calcium in WT 
and Vdr null mice throughout pregnancy. Although the difference was not statistically 
significant, the V dr null value appeared lower than WT at baseline. Early in pregnancy, 
both WT and Vdr nulls have a trend toward increased urine calcium levels and the values 
become more similar. During late pregnancy, both genotypes have a trend toward 
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Figure 3.8 Preliminary results for serum ionized calcium levels at baseline and late 
pregnancy in Vdr null mice. Mice were raised on a nonnal I% calcium diet for I 0 
weeks. Baseline whole tail blood was collected and analyzed immediately for ionized 
calcium. They were then switched to a 2% calcium, 1.25% phosphoru and 20% lactose 
enriched diet and mated. An additional ionized calcium measurement was obtained at 
late pregnancy. WT baseline serum ionized calcium (1 .17mmoi/L, N=8) is indicated by 
the dotted line. 
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Figure 3.9 Serum ionized calcium in virgin Vdr null mice while on regular diet (10 
weeks) and while receiving the enriched diet. Mice were raised on a nonnal 1% 
calciumdiet for 10 weeks. Whole tail blood was collected and analyzed immediately for 
ionized calcium. They were then switched to a 2% calcium, 1.25% phosphorus and 20% 
lactose enriched diet. Serial ionized calcium measurements were obtained at 12, 20 and 
22 weeks and expressed as mean±SE. WT mean ionized calcium level (1.17mmoi/L, 
N=8) is indicated by the dotted line. 
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Figure 3.10 Urine total calcium levels in WT (blue) and Vdr null (red) mice at 
baseline and throughout pregnancy. Mice were raised on a nonnal I% calcium diet for 
I 0 weeks. They were then switched to a 2% calcium, 1.25% phosphorus and 20% lactose 
enriched diet. After at least 7 days, baseline urine was collected and the mice were 
mated. Serial urine samples were collected at gestation day 7 of pregnancy (early 
pregnancy), ge tation day 18.5 of pregnancy (late pregnancy). Urine total calcium was 
measured using a calcium spectrophotometric assay (Diagnostic Chemical Ltd) and 
expressed relative to the urine creatinine concentration (mmol calcium/mmol creatinine, 
mean±SE). 
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decrease in urine calcium levels and the values remain similar, suggesting that Vdr null 
urine calcium excretion is becoming normalized. 
3.4.3 Secondary hyperparathyroidism 
Serum PTH was measured to determine if the increase in duodenal calcium 
absorption lessened secondary hyperparathyroidism in Vdr nulls during pregnancy. 
Serum PTH in Vdr null and WT mice at baseline and during pregnancy are shown in 
Figure 3.11. Baseline serum PTH levels were significantly higher in Vdr nulls as 
compared to WT. During pregnancy, serum PTH decreased in Vdr nulls to levels that 
were not significantly different from WT levels. 
Since secondary hyperparathyroidism is associated with increased bone turnover, 
a decrease in serum PTH should be accompanied by a decrease in bone turnover. I 
measured serum osteocalcin and urine DPD, markers of bone formation and resorption 
respectively, to determine if bone turnover was decreased in Vdr nulls during pregnancy. 
Serum osteocalcin levels in WT and V dr null mice during pregnancy are 
displayed in Figure 3.12. At baseline, serum osteocalcin was elevated in V dr null mice 
as compared to WT. By late pregnancy, Vdr null serum osteocalcin reduced significantly 
(p<0.05) to normal WT levels. WT osteocalcin levels did not change during pregnancy. 
Urine DPD/creatinine levels in WT and V dr null mice are shown in Figure 3. 13. 
Vdr null DPD levels were significantly increased (p<0.05) at baseline but decreased 
significantly (p<0.05) to WT levels during pregnancy. 
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Figure 3.11 Serum PTH levels in WT (blue) and Vdr null (red) mice at baseline and 
during pregnancy. Mice were raised on a normal 1% calcium diet for I 0 weeks. They 
were then switched to a 2% calcium, 1.25% phosphorus and 20% !acto e enriched diet. 
After at least 7 days, baseline tail blood serum was collected and the mice were mated. 
Serial tail blood serum samples were collected at gestation day 7 (early pregnancy) and 
gestation day 18.5 (late pregnancy). Serum PTH levels were detected using a Rat Intact 
PTH ELISA kit (lmmutopics, Inc) and expressed as mean±SE. 
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Figure 3.12 Serum osteocalcin levels in WT (blue) and Vdr null (red) mice at 
baseline and during pregnancy. Mice were rai ed on a nonnal I% calcium diet for I 0 
weeks. They were then switched to a 2% calcium, 1.25% phosphorus and 20% lactose 
enriched diet. After 7 days, baseline tai l serum was collected and the mice were mated. 
Serial tail serum samples were collected at gestation day 7 (early pregnancy) and 
gestation day 18.5 (late pregnancy). Serum osteocalcin was measured u ing the Mouse 
Osteocalcin IRMA kit (rmmutopics, Inc) and expressed as mean±SE. 
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Figure 3.13 Urine DPD levels in WT (blue) and Vdr null (red) mice at baseline and 
during pregnancy. Mice were raised on a normal 1% calcium diet for 10 weeks. They 
were then switched to a 2% calcium, 1.25% phosphorus and 20% lactose enriched diet. 
After at least 7 days, baseline urine was collected and the mice were mated. Serial urine 
samples were collected at gestation day 7 (early pregnancy) and gestation day 18.5 of 
pregnancy (late pregnancy). Urine DPD was detected using the Metra DPD Enzyme 
Immunoassay (EIA) (Quidel) and Urine Creatinine was determined using the Creatinine-
S spectrophotometric assay (Diagnostic Chemicals Limited). Urine DPD levels are 
expressed relative to the urine creatinine concentration as mnol DPD/mmol Creatinine 
(mean±SE). 
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3.5 Bone histology and histomorplzometry 
In order to determine if the rachitic V dr null skeleton was repaired during 
pregnancy, the tibias were examined histologically. Goldner ' s trichrome stain of 
undecalcified tibia cross sections are shown in Figure 3. I 4 (A-E). WT tibias (A,D) 
displayed a normal morphology and an organized growth plate (indicated by white 
arrows). Vdr null tibias had an abnormal rachitic morphology, disorganized growth plate 
(indicated by white arrows) and marked fibrosis (not shown) at both baseline (B,E) and 
pregnancy (C). Von Kossa stains of Vdr null tibia from baseline and late pregnancy are 
shown in Figure 3.I4 (H,I). Tibias from pregnant Vdr nulls displayed more mineral than 
baseline. 
Vdr null undecalcified tibias were also examined histomorphometrically to 
determine if the increase in BMC in Vdr nulls during pregnancy was due to an increase in 
the formation of new bone or an increase in osteoid mineralization. Table 3. 4 displays 
the histomorphometry results for Vdr nulls at baseline and late pregnancy. Interestingly, 
there was no difference in bone volume, trabecular spacing, trabecular thickness or 
trabecular number during pregnancy as compared to baseline. In contrast, significant 
decreases were observed in osteoblast and osteoclast number, resorptive surface, osteoid 
surface and osteoid thickness in pregnant Vdr nulls as compared to baseline. This is also 
displayed histologically in Figure 3. I 4 (F, G). Toluidine blue stains of Vdr null tibia 
trabeculae from baseline (F) showed more osteoid (arrows indicate clear layer of osteoid) 
than late pregnancy (G). 
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Fi ure 3.14 Undecalcified tibia histology. A,B,C. Goldner's trichrome stain of WT 
baseline (A) Vdr null baseline (B) and Vdr null late pregnancy (C) . D,E. Goldner's 
trichrome stain of WT baseline (D) and Vdr null baseline (E) growth plates. 
F, G. Toluidine blue stains of tibia trabeculae from Vdr null baseline (F, Arrows indicate 
clear layer of osteoid) and late pregnancy (G). H,l. Von Kossa stain of Vdr null tibias 
from baseline (H) and late pregnancy(/). Mice were raised on a normal1 % calcium 
chow for 10 weeks. They were then switched to a 2% calcium, 1.25% phosphorus and 
20% lactose enriched diet. After at least 7 days (baseline) or at late pregnancy 
(gestation day 16.5) tibias were harvested, fixed, embedded, sectioned and stained. 
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Units Baseline Pregnancy 
BY/TV % 7.5± 1.2 7.7±1.2 
Tb.Th !liTI 33 . 1±3.9 39.1±3.9 
Tb.Sp !liTI 47 1±133 502±133 
Tb.N #/mm 2.2±0.6 2.2±0.6 
N.Ob/BPm #/mm 18.3±3.7 0.3±3.7'' 
N.Oc/BPm #/mm 2.6±0.5 0.8±0.5d 
OcS/BS % 9.5±1 .6 3.0±1.6c 
OS/BS % 19.3±3.5 0.4±3S 
O.Th !liTI 3.9±0.7 0.9±0.7° 
a b . c d. p<0.02, p<0.03 , p<0.05, p<0.08 
Table 3.4 Histomorphometry results for Vdr null tibias at baseline and late 
pregnancy. The parameters measured were as follows: Bone volume (BY/TV)· 
Trabecular number (Tb.N); Trabecular thickness (Tb.Th); Trabecular spacing (Tb.Sp); 
Osteoblast number (N.Ob/BPm); Osteoclast number (N.Oc/BPm); Osteoclast surface 
(OcS/BS); Osteoid surface (OS/BS). The results are expressed as mean±SE. 
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4. Discussion 
I ,25(0H)2D3 and the VDR are essential for normal calcium and bone 
metabolism. Without the VDR, intestinal calcium absorption is reduced and the skeleton 
is stripped of calcium in order to maintain adequate levels in the serum. Vitamin D 
deficient rats and mice lacking either 1-a hydroxylase or the Vdr have poor intestinal 
calcium absorption, secondary hyperparathyroidism, hypocalcemia, rickets and an 
undermineralized skeleton (83-85). Pregnancy and lactation impose large demands on 
maternal calcium homeostasis. I investigated Vdr null mice to determine if 1,25(0H)2D3 
and the VDR were essential for calcium balance in females during the reproductive 
periods. 
4.1 Bone mineral content 
Adult V dr null mice have rickets and osteomalacia. I wondered how these 
malformed, undermineralized skeletons would react when faced with the calcemic 
demands of pregnancy and lactation. I first investigated changes in BMC in Vdr null and 
WT mice during pregnancy, lactation and post-weaning recovery. 
WT mice gained 7.13% total BMC during pregnancy, lost 18.05% during 
lactation and recovered to baseline post weaning. These data are consistent with previous 
research in WT mice in our lab (71, 72). The small increase in BMC during pregnancy 
may be an adaptation to prepare for the losses in BMC that occur during lactation in order 
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to provide calcium to the milk. After lactation, the BMC is rapidly regained without 
pathological consequences on the mother. 
At baseline, Vdr nulls have approximately two thirds the an1ow1t of skeletal 
mineral as WT controls. This data is consistent with other studies involving vitamin D-
depleted rats and Vdr null mice (80, 84, 85). Surprisingly, Vdr null mice experienced a 
57% increase in BMC during pregnancy, which normalized their BMC to WT levels. 
These results suggest that there is an increase in either new bone formation or 
mineralization of osteoid during pregnancy so that the Vdr null skeleton contains the 
normal amow1t of mineral. Previous research supports these results. Rummens el a!. 
(95) reported that bone density increased during pregnancy in the Leuwen Vdr knockout 
mouse on both regular calciwn and enriched calcitm1 diets. Furthermore, Halloran et a!. 
(80) also documented that total bone calcium tended to increase in vitamin D deficient 
female rats during pregnancy. 
Vdr nulls lost 36% BMC during lactation and recovered post-weaning to a value 
that was 49% higher than the pre-pregnancy baseline. These data do not agree with 
studies by Halloran et al. (80) or Miller et al. (96), who both observed that vitamin D 
deficient rats replaced some mineral after weaning but did not fully recover to baseline. 
This may be due to the fact that different models were used. It is possible that vitamin D 
deficient rats do not recover from lactation. These groups also used ash weight and 
histomorphometrical methods to estimate changes in bone mineral content which may 
provide a larger source of error and produce different results. 
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The skeleton is composed of both dense cortical bone and metabolically active 
spongy, trabecular bone. The hindlimb contains mostly cortical bone and the spine, 
trabecular bone. Regional changes in spine and hindlimb BMC were analyzed in order to 
determine if the changes in BMC affected involved one or both bone types. Gains and 
losses of BMC in the spine and hindlimb were similar to the changes in whole body BMC 
in Vdr null and WT mice. This suggests that the changes in BMC during the 
reproductive periods involve both trabecular and cortical bone. 
Collectively, the results suggest that the VDR is not necessary for the 
maintenance of skeletal mineral metabolism during pregnancy and lactation. They also 
suggest that reproduction may be advantageous to the skeleton in mice lacking the Vdr. 
As bone is lost or resorbed during lactation, it is possible that new bone is formed to 
replace the abnormal bone, thus repairing the skeleton. 
It was evident that the diet could be responsible, at least in part, for the increase in 
BMC. Rwnmens et al. (95) indicated that Leuwen Vdr nulls on a regular diet 
experienced an increase in trabecular bone while Vdr nulls who received the enriched diet 
at diagnosis of pregnancy, showed increases in both trabecular and cortical bone. For this 
reason, I measured changes in total BMC in non-pregnant Vdr nulls both before receiving 
the diet (10 weeks of age) and while on the diet (14, 18,22 weeks). The preliminary 
data indicate that after 12 weeks on the diet, non-pregnant Vdr null mice experienced a 
gradual increase in BMC to a final value of 58%. This suggests that the enriched diet is 
responsible for at least some of the increase in BMC in V dr nulls. 
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To further explore this issue, I also investigated the amount of time between 
baseline and late pregnancy scans and the amount of bone that was gained for each Vdr 
null. This would determine if there were a relationship between the amount of time 
consuming the diet and the amount ofBMC gained. Three Vdr null mice had a mean 3.5 
weeks on the enriched diet and gained 41% BMC during that time. Two V dr null mice 
had a mean 14 weeks on the diet and gained 71%. These results show that pregnant V dr 
null mice gained more BMC after both 3.5 and 14 weeks on the diet than non-pregnant 
V dr null mice. Again, this suggests that the enriched diet is responsible for at least some 
ofthe increase in BMC but cannot account for all of the BMC that is achieved during 
pregnancy. 
In future studies, it would be necessary to determine exactly how much the diet 
influences BMC during pregnancy and lactation in Vdr null mice. To achieve this, BMC 
measurements should be obtained during reproduction in Vdr nulls on a regular calcium 
diet, if it is physiologically possible. Vdr nulls are capable of completing pregnancy on a 
regular calciw11 diet (86) but it is not known ifthey can lactate normally. If the enriched 
diet were required for lactation, then the mice should be removed from the high calcium 
diet post weaning. This would at least determine if the enriched diet were necessary for 
the increase in BMC during post-weaning recovery. 
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4.2 Duodenal calcium absorption and gene expression 
4.2.1 Duodenal calcium absorption 
During pregnancy, there is an increase in intestinal calcium absorption in order to 
meet the demands of the mineralizing fetal skeleton. It has been presumed that the 
increase in calcium absorption is mediated by 1 ,25(0H)2D3 and the VDR. I wondered if 
the increase in BMC in the Vdr nulls during pregnancy was due to an increase in calcium 
absorption that was independent of the VDR. This led me to investigate intestinal 45Ca 
absorption in Vdr null and WT mice at baseline and late pregnancy (gestation day 16.5) 
using an in situ ligated loop technique. This teclmique utilizes a physiological 
concentration of calcium [CaCh, (2 mmol/L)] so that active transcell ular calcium 
transport predominates (97, 98). The experiment was performed on gestation day 16.5 
because it is the time when the transfer of calcium across the placenta to the fetus is at 
peak levels. 
As shown in Figure 3. 6, duodenal 45Ca absorption was reduced in the non-
pregnant Vdr null as compared to WT. This supports that a loss ofVDR leads to a 
decrease in the active transport of calcium in the duodenum and it has also been observed 
in the Tokyo and Leuwen Vdr knockout strains (20, 99). 
Surprisingly, 45Ca absorption increased significantly in pregnant Vdr nulls as 
compared to baseline. This suggests that the increase in intestinal calcium absorption 
during pregnancy does not require the VDR Previous evidence also indicates that 
1 ,25(0H)2D3 and the VDR are not required for intestinal calcium absorption during 
pregnancy. For example, the increase in calcium absorption during pregnancy has been 
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shown to precede the rise in 1,25(0H)2D3 levels (67). In addition, Halloran et al. (68) 
and Brommage et al. (69) documented that intestinal calcium absorption was increased 
during pregnancy in vitamin D deficient rats. 
The results suggest that during pregnancy, unique mechanisms may be activated 
to stimulate duodenal calcium absorption in order to achieve ideal physiological 
conditions for the fetus and to prepare for lactation. In addition, the increase in 45Ca 
absorption in Vdr nulls may explain, at least in part, the increase in BMC during 
pregnancy. An increase in the active absorption of calcium would increase the an1ount of 
calcium that is available for bone formation or mineralization. 
The increase in intestinal calcium absorption may be caused by hormones other 
than 1,25(0H)2D3. Takeuchi et al. (70) reported that placental lactogen stimulates 
calcium transfer during pregnancy. Studies by Ajibade et al.(26), in non-pregnant 
vitan1in D deficient mice, have shown that prolactin injections stimulated a 3 fold 
increase in duodenal calcium absorption. Placental lactogen is characteristically similar 
to prolactin and ultilizes the prolactin receptor. It is likely that both are capable of 
stimulating intestinal calcium absorption; however, placental lactogen is elevated during 
pregnancy while prolactin is not. Thus, placental lactogen could be responsible for 
increasing duodenal calcium absorption during this time. 
Vdr null mice lack a functional Vdr but do not lack 1 ,25(0H)2D3. Several studies 
have shown, however, that 1,25(0H)2D3 may stimulate both active and passive intestinal 
calcium absorption through VDR-independent mechanisms (29, 30, 100, 1 01). It has 
been proposed that in these situations, 1 ,2S(OH)2D3 acts similar to growth factors or 
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peptide hormones to initiate signaling pathways to activate rapid responses (29). This 
may occur tlu·ough a unique receptor on the plasma membrane (1 02). Intestinal calcium 
absorption also increases in vitamin D deficient rats during pregnancy (68) therefore, it is 
unlikely that non-genomic actions of 1 ,25(0H)2D3 are responsible for the increase 111 
intestinal calcium in Vdr null mice. 
There is also increasing evidence that the VDR may have a unique non-
transcriptional role in mediating plasma membrane signaling (103-105). Although the 
Vdr knockout model used in my experiments has a mutation in the second zinc finger of 
the VDR DNA binding domain, this may not inhibit non-transcriptional actions of the 
VDR in my null mice. It is possible that the mutated VDR initiates signaling to stimulate 
calcium absorption during pregnancy. 
My values for percentage duodenal calcium absorption in non-pregnant mice were 
much higher than values recorded by Song et al. (99). I reported a 71% and 85% 
absorption in non-pregnant Vdr null and WT, respectively. Song et al. (99) observed 
16% and 55% for Vdr null and WT mice on a 0.5% calcium diet and 20% and 18% on a 
2% calcium diet. Their data suggested that the enriched calcium diet decreases the active 
transport of calcium. It is my belief, however, that the diet increa ed passive duodenal 
calcium absorption in my experiments, thus causing the high baseline values. Although 
the ligated loop technique is designed to measure the active absorption of calcium across 
the duodenum, passive absorption may also occur during the experiment in these fasted 
mice. 
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The diet may cause an increase in passive calcium absorption in two ways. First, 
a high calcium diet will increase the concentration of calcium in the lumen of the 
intestine. Even though the mice were fasted, remnants of the diet may still exist after 
fasting. This would increase the concentration gradient between the lumen and the blood 
and therefore increase paracellular calcium absorption across the mucosal cells. 
Secondly, the diet contains 20% lactose, a major disaccharide in milk, which is known to 
increase calcium absorption in the absence of vitamin D (36). The exact mechanism of 
how this occurs is a matter of controversy, however, the breakdown of lactose to glucose 
and galactose may be important (36). In this process lactose may increase the 
bioavailability of calcium in the intestine, making it more readily absorbed, which would 
prolong the passive vitan1in D-independent absorption of calcium in the ileum (1 06). 
Alternately, lactose may act on the intestinal mucosa to increase its permeability, possibly 
by increasing the space of the intercellular tight junctions ( 1 07). 
A diet-induced increase in the passive absorption of calcium across the 
duodenum could also explain the increase in BMC that was observed in non-pregnant 
mice. This would provide more calcium for mineralizing the skeleton, resulting in a 
steady increase in BMC in non-pregnant Vdr null mice with undermineralized skeletons. 
4.2.2 Duodenal gene expression 
To further investigate the cellular mechanisms involved in the upregulation of 
intestinal calcium absorption in Vdr null mice during pregnancy, I performed a whole 
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genome microarray analysis of gene expression in the duodenum of V dr null and WT 
mice at baseline and late pregnancy. The microarray results for Trpv6, Pmcal b and 
SgJOO are shown in Table 3.2. These results were confirmed using real time RT-PCR 
(Table 3. 3, Figure 3. 7). 
The microarray data indicated that Trpv6 expression was reduced in non-pregnant 
Vdr nulls as compared to WT (p<0.005). This agrees with other studies in Leuwen and 
Tokyo Vdr knockout mice on low, normal or high calcium diets (20, 99). 
During pregnancy, Trpv6 expression decreased in WT mice as compared to 
baseline (p<0.005). In contrast, Trpv6 expression increased 4.8 fold during pregnancy in 
Vdr nulls as compared to baseline (p<0.005). As a result, Tlpv6 mRNA expression 
increased to equal (microarray) or surpassed (real time RT-PCR, Figure 3. 7) WT baseline 
levels. These results indicate that Trpv6 expression is upregulated in V dr nulls 
independently of the Vdr during pregnancy, thus leading to an increase in the active 
absorption of intestinal calciwn. Futme studies will also determine if TRPV 6 protein 
expression is upregulated in Vdr null mice dming pregnancy. 
The results from the microarray and real time RT-PCR analysis of Ttpv6 
expression differ in magnitude and significance. Approximately 32 PCR cycles were 
required to amplify the template suggesting that Trpv6 mRNA is expressed in very small 
amounts in the san1ples. Real time RT-PCR accurately detects very small amounts of 
mRNA and may produce more reliable results. 
The increase in Trpv6 expression in V dr nulls dming pregnancy does not appear 
to be diet-related. Trpv6 expression was reduced in Vdr nulls at baseline, while receiving 
72 
the enriched diet. WT mice were also receiving the high calcium diet and did not 
experience an increase in Trpv6 expression dming pregnancy. Also, as mentioned, 
previous research by VanCromphaut eta!. (20) and Song et al. (99) reported that Trpv6 
expression was reduced in non-pregnant Leuwen and Tokyo Vdr knockouts, regardless of 
the diet. This further supports that Vdr null Trpv6 expression is increased during 
pregnancy and not as a consequence of the high calcium diet. 
These data suggest that unique VDR-independent mechanisms are activated 
during pregnancy, which stimulate Trpv6 expression leading to an increase in the active 
transport of calcium across the duodenum. Previous studies have shown that prolactin 
stimulates Trpv6 expression (26). As placental lactogen has been shown to stimulate 
intestinal calcium absorption independently of 1,25(0H)2D3 during pregnancy and act 
through the prolactin receptor, it may also be the factor that is responsible for stimulating 
the increase in Trpv6 expression. To fmther investigate the mechanisms activating this 
system, future studies will focus on measuring the serum levels of these likely candidates. 
The results also suggest that calbindin-D9K is not required for the increase in 
duodenal calcium absorption in Vdr null during pregnancy. SgJOO mRNA expression in 
V dr nulls was normal at baseline and late pregnancy. This is not consistent with previous 
research which reported that intestinal Sgl 00 mRNA expression was lower in Boston and 
Tokyo Vdr null mice as compared to WT (99, 1 08). These groups also showed, however, 
that Sgl 00 mRNA expression is reduced in WT mice receiving the 2% enriched calcium 
as compared to WTs fed a regular diet. If my WT baseline expression values are 
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decreased due to the enriched diet, then Vdr null expression would appear normal. This 
may explain the why my results differ from previous research. 
Pmcal b mRNA expression was also normal in Vdr nulls at baseline. These 
results agree with previous studies which also found that Pmcal b mRNA expression was 
normal in non-pregnant Leuwen and Tokyo Vdr nulls (20). Smprisingly, Pmcal b mRNA 
expression did not increase dming pregnancy. This suggests that Ca2+ A TPase is not 
required for the upregulation of intestinal calcium transfer in Vdr nulls dming pregnancy, 
however, Ca2+ ATPase expression may remain the same while its activity increases. In 
future studies, protein expression of calbindin-D9K and Ca2+ ATPase and the activity of 
Ca2+ ATPase will be examined. 
It is possible that I did not see changes in the expression of Sg 100 and Pmcal b 
because of the way I harvested the sample. Changes in expression that were directly 
related to the increase in calcium absorption would have occurred in the mucosal layer. 
Harvesting a section of the whole duodenum, which also contains the intestinal muscle 
wall and pancreatic tissue, may have masked important changes that could have occurred 
in the epithelium. This technique could be improved by obtaining duodenal epithelial 
scrapings, rather than harvesting the whole duodenum. 
All other significant changes in duodenal gene expression are shown in Appendix 
A and B. Although the expression of these genes was not further explored in this thesis, 
some of them are deserving offutme investigation. For example, the microarray analysis 
also appeared to support the theory that the lactose in the diet upregulates passive calcium 
absorption (Appendix A). The data indicated that lactase mRNA was upregulated 4.3 
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fold (p<0.05) in Vdr nulls at baseline as compared to WT (Al). Lactase expression was 
also 2.22 fold (p<0.05) in Vdr nulls during pregnancy as compared to pregnant WTs (A4) 
and 1.6 fold (NS, data not shown) in pregnant WTs as compared to baseline. Lactase is 
an enzyme which is expressed on the brush border membrane of the duodenal mucosal 
cell that is essential for the break down of lactose to glucose and galactose. Prolonged 
exposure to the diet may upregulate lactase expression, resulting in the breakdown of 
lactose that ultimately initiates signaling to cause an increase in paracellular calciw11 
absorption. 
In addition, duodenal expression of claudin-4 was decreased 0.46 (p<0.005) in 
pregnant Vdr nulls as compared to baseline (A2) and 0.42 (p<0.05) as compared to 
pregnant WTs (A4). The claudin family of proteins are important in the regulation of 
tight junctions (1 09). 1,25(0H)2DJ has been shown to stimulate claudin-2 and claudin-
12 expression to increase intestinal paracellular absorption (30). These results further 
support that claudin expression is regulatd by 1 ,25(0H)2D3 and the V dr but do not appear 
to explain the mechanism causing the increase in Vdr null intestinal calcium absorption 
during pregnancy. 
Furthermore, duodenal expression of the uncharacterized eDNA sequence 
A Y05357 is increased 3.42 (p<0.05) in Vdr nulls at baseline as compared to WT's (Al) 
but is decreased 0.27 (p=0.005) in pregnant Vdr nulls as compared to pregnant WT's 
(A2). The role of this gene in pregnant Vdr nulls may also deserve further exploration in 
the future. 
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It is possible that the analysis of the microarray data is limited due to the small 
sample sizes used in the experiment. This was caused by problems with RNA quality. 
The Centre for Applied Genomics' (The Hospital for Sick Children, Toronto) protocol 
recommends that only samples with a RlN2:7 be used for microarray analysis. Only 50% 
of my samples met this requirement because there was significant degradation observed 
in the other half of the samples. As a result, only two samples (as opposed to fom) per 
genotype, per timepoint were chosen for microarray analysis, which greatly reduced the 
sample sizes for the experiment. Due to time constraints and the low probability of Vdr 
null survival to 10 weeks ( ~25%), acquiring more samples was not possible. Despite the 
small sample sizes, good quality RNA was used for these microarray experiments and the 
results were confirmed using real-time PCR, suggesting that the data are accurate. 
4.3 Impact on calcium homeostasis 
Non-pregnant Vdr null mice have hypocalcemia, secondary hyperparathyroidism, 
osteomalacia and rickets. Next I wanted to determine if the increase in intestinal calcium 
absorption during pregnancy also repaired calcium homeostasis in Vdr nulls. 
4.3.1 Serum calcium 
Serum ionized calcium was measured to determine if the increase in intestinal 
calcium absorption in Vdr nulls during pregnancy also normalized serum ionized calcium 
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levels. Unfortunately, only preliminary data could be obtained for ionized calcium. 
Reagents for the ionized calcium machine in om laboratory were no longer commercially 
available and no other ionized calcium measuring device was available locally. As a 
result, the sample sizes for my ionized calcium data were very small. 
The non-pregnant Vdr null was hypocalcemic at baseline but normalized serum 
ionized calcium to WT levels by late pregnancy. These preliminary data suggest that 
pregnancy normalized ionized calcium levels in Vdr null mice, however, more data is 
needed to be conclusive. 
To further exan1ine if ionized calcium were normalized by the enriched diet, I 
measmed ionized calcium in non-pregnant Vdr null mice on a regular calcium diet (1 0 
weeks of age), after receiving the high calcium diet at 12 weeks, 20 weeks and 22 weeks 
of age. Non-pregnant Vdr null mice were hypocalcemic on the regular diet. Vdr null 
ionized calcium normalized to WT levels between 12 and 20 weeks of receiving the 
enriched diet. This suggests that the high calcium diet will eventually normalize ionized 
calcium in Vdr null mice. Others have shown that a high calcium diet normalized serum 
calcium in vitan1in D deficient rats (110), Vdr knockout mice (87, 89) and l ,a-
hydoxylase knockout mice (111) that would otherwise be hypocalcemic if fed a regular 
1% calciwn diet. Due to the lack of data between 12 and 20 weeks it is difficult to 
determine if the normalization of serum calci urn would occur faster in pregnant V dr nulls. 
It will be necessary to repeat this experiment to obtain more data. This will help 
distinguish how pregnancy and the diet independently influence serum calcium in Vdr 
null mice. 
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4.3.2 Urine calcium 
I measured urine calcium to determine if calcium excretion was altered during 
pregnancy in Vdr null mice. At baseline, Vdr null urine calcium is not significantly 
different but appears reduced as compared to WT. This may suggest that because Vdr 
nulls have decreased duodenal calcium absorption, they need to reclaim more calcium 
back into the circulation. Conversely, it may indicate that WT mice are excreting more 
calcium because ofthe diet-induced increase in intestinal calcium absorption. 
Early in pregnancy, urine calcium is increased in both Vdr null and WT mice. 
This supports the 45Ca absorption results because an increase in duodenal calcium 
absorption would increase calcium availability in both genotypes and require that the 
kidneys remove more calcium from the circulation. By late pregnancy, urine calcium 
excretion shows a reducing trend in both null and WT mice, suggesting that more 
calcium is being reclaimed back into the circulation in order to meet the demands of the 
mineralizing fetal skeleton. 
4.3.3 Secondary hyperparathyroidism and bone turnover 
Non-pregnant Vdr null mice have secondary hyperparathyroidism which is 
associated with increased bone turnover or remodeling. I measured serum PTH and 
biomarkers of bone turnover to determine if secondary hyperparathyroidism was 
decreased in Vdr nulls during pregnancy. 
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Vdr null mice had secondary hyperparathyroidism at baseline; serum PTH was 
significantly elevated as compared to WT. During early and late pregnancy, serum PTH 
decreased to levels that were not statistically different from WT. This suggests that 
secondary hyperparathyroidism in Vdr nulls is lessened during pregnancy. These results 
were expected since an increase in intestinal calcium absorption during pregnancy would 
possibly increase serum calcium, leading to a decrease in secondary hyperparathyroidism. 
The decreased PTH levels may be related to the enriched diet. If the diet 
increases the passive absorption of calcium, then serum calcium normalizes, resulting in a 
decrease in PTH. The diet was shown to prevent secondary hyperparathyroidism 
(maintain normal PTH levels) in both rats with diet-induced vitamin D deficiency (88) 
and Vdr null mice (fed diet at weaning) (87). However, Song eta!. (99) observed that 
PTH levels remained elevated in Tokyo Vdr null mice that were fed the high calcium diet 
from weaning. To address this issue, further research is necessary to determine if serwn 
PTH levels are altered in non-pregnant Vdr nulls receiving the calcium enriched diet. 
Since there was a decrease in serum PTH in pregnant Vdr null mice, I wondered if 
there were also a decrease in bone turnover. I measured serum osteocalcin, a marker of 
bone formation, and urine DPD (Figure 3.13), a marker of bone resorption, to determine 
if these processes were decreased in pregnant V dr nulls. 
At baseline, serum osteocalcin was increased in Vdr nulls as compared to WT, 
suggesting that bone formation is increased. During pregnancy, Vdr null serum 
osteocalcin decreased to WT levels, indicating that bone formation decreased. This 
suggests that the increased BMC in Vdr nulls during pregnancy did not result from an 
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increase in the formation of new bone. It is possible, at baseline, osteoblasts are laying 
down the bone matrix at a high rate but due to hypocalcemia, calcium may not be 
available to mineralize the matrix. During pregnancy, Vdr null intestinal calcium transfer 
is increased, resulting in an increase in the availability of calcium in the serum and 
mineralization of the previously laid bone matrix at a time when osteoblast activity is 
decreasing. 
Urine DPD was significantly increased in Vdr nulls at baseline suggesting that 
bone resorption is increased during this time. During pregnancy, Vdr null urine DPD 
decreased to WT levels suggesting that bone resorption was decreasing. These results 
support the BMC data. Bone resorption is decreasing, allowing bone mineral content to 
mcrease. 
Collectively, the increased serum osteocalcin and urine DPD levels at baseline 
suggest that bone turnover is elevated in non-pregnant Vdr null mice. Likewise, the 
decrease in osteocalcin and DPD levels in Vdr nulls during pregnancy suggest that bone 
turnover is decreased. These data demonstrate that secondary hyperparathyroidism and 
bone turnover are reduced in Vdr null mice during pregnancy. 
4.4 Bone histology and histomorphometry 
The biomarker data indicated that bone turnover decreased in Vdr nulls during 
pregnancy. This suggests that the increased BMC during pregnancy was not due to an 
increase in bone formation but rather an increase in osteoid mineralization. 
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To further investigate this, I examined w1decalcified tibias to determine if bone 
morphology improved in Vdr nulls during pregnancy and to further confirm that bone 
mineral content increased (Figure 3.14). At baseline, Vdr null tibias had an abnormal 
rachitic morphology (B), a disorganized growth plate (E) and marked fibrosis (not 
displayed) as compared to WT (A, D). This rachitic phenotype was also shown during 
pregnancy in Vdr null mice (C). This suggests that the increased BMC and reduced 
secondary hyperparathyroidism that occurred in Vdr nulls during pregnancy did not 
repair the rachitic bone phenotype. This data supports the biomarker results and suggests 
that the increase in BMC in Vdr nulls during pregnancy is a result of an increase in the 
mineralization of pre-existing osteoid, rather than an increase in the formation of new 
bone. Analysis of tibia von Kossa stains supported the BMC data. Pregnant V dr nulls (I) 
showed increased mineral as compared to baseline (H). 
Vdr null and WT undecalified tibias were also analysed using histomorphometry 
to confirm if the increased BMC during pregnancy was the result of an increase in 
osteoid mineralization in Vdr nulls (Table 3.4). Interestingly, there was no significant 
difference in bone volwne, trabecular thickness, trabecular spacing or trabecular number 
in pregnant Vdr nulls as compared to baseline. These results indicate that bone volume 
did not change during pregnancy in Vdr nulls and support the notion that the increase in 
BMC was not due to the formation of new bone. Surprisingly, significant decreases were 
observed in osteoblast and osteoclast numbers and resorptive surface in pregnant Vdr 
nulls which further supports the view that bone turnover is decreased in Vdr nulls during 
pregnancy. Osteoid surface and osteoid thickness also significantly decreased in 
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pregnant Vdr nulls suggesting that the amount of osteoid is decreasing and thus being 
mineralized to form bone. This is also displayed histologically. The amOtmt of osteoid 
was greater in Vdr null tibias at baseline (indicated by atTows in F) than late pregnru1cy 
(G). This supports that the increase in Vdr null BMC during pregnancy was due to an 
increase in the mineralization of osteoid rather than the formation of new bone. 
4.5 Proposed model 
In an attempt to explain the results of my experiments, I an1 proposing the 
following models (Figure 4.1, 4.2). Figure 4.1 displays how the active transcellulru· 
transport of calcium is upregulated in Vdr nulls. During pregnancy, the presence of 
factors/hormones activate unique mechanisms in the Vdr null to increase the expression 
of duodenal Trpv6, thus driving a1.1 increase in the active absorption of calcium. I suspect 
that Sgl 00 and Pmcal bare also upregulated at the protein level or show increased 
activity. As a result, serum PTH, urine calcium, bone turnover and BMC ru·e normalized, 
allowing the Vdr null to follow through a normal pregnancy. Figure 4.2 displays how the 
diet causes an increase in the passive paracellular absorption. The enriched calcium diet 
increases the concentration of calcium in the lumen, thus increasing the concentration 
gradient, favoring the movement of more calcium ions into the blood. I suspect that this 
is occurring in both Vdr null and WT mice. This is further encouraged by an increase in 
the expression of lactase. Lactase digests dietru·y lactose and increases paracellular 
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0 0 Trpv6 .----------... 
INTESTINAL 
LUMEN 
NON-PREGNANT 
Vdr null mice 
PREGNANT 
Vdr null mice ??? 
0 
0 0 
0 
Ca2.ATPase 
BLOOD 
Figure 4.1 Proposed model for the increase in transcellular absorption in Vdr null 
mice during pregnancy. During pregnancy, the presence offactorslhonnones activate 
unique mechanisms in the Vdr null during pregnancy increase the expression of duodenal 
Trpv6, thus driving an increase in the active absorption of calcium. 
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INTESTINAL 
LUMEN 
Receiving a regular calcium diet 
Receiving an enriched calcium diet 
BLOOD 
Figure 4.2 Proposed model for the effect of the calcium and lactose enriched diet on 
paracellular absorption. The enriched calcium diet increases the concentration of 
calcium in the lumen, thus increasing the concentration gradient, favoring the movement 
of more calcium ions into the blood. This is further encouraged by an increase in the 
expression oflactase. Lactase digests dietary lactose and increases paracellular 
absorption, probably through an increase in tight junction penneability. 
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absorption, probably through an increase in tight junction permeability. Over time, this 
small increase in calcium absorption would provide more calcium in the serum and 
eventually result in a steady increase in BMC in undermineralized Vdr null skeletons. 
For this reason, I believe that the diet is, at least in part responsible for the increase in 
BMC in pregnant and post-lactating Vdr null mice. The increase in passive absorption 
would have no visible effect on BMC in WT skeletons because they are not 
w1dermineralized. 
4.6 Summary and conclusion 
Vdr null mice were able to achieve a normal pregnancy, lactation and recovery. 
During pregnancy, Trpv6 expression was increased in Vdr null mjce leading to an 
increase in intestinal calcium absorption. The increase in calcium absorption increased 
serum calcium levels, resulting in a decrease in secondary hyperparathyroidism, an 
increase in osteoid mineralization and ultimately an increase in BMC. Experiments 
involving non-pregnant Vdr null mice suggest that the calcium and lactose enriched diet 
is partly responsible for the increase in BMC and normalization of calcium homeostasis, 
however, the contribution appears to be of a lesser magnitude than pregnancy. 
In conclusion, the VDR is not required to regulate calcium and bone homeostasis 
during pregnancy. 
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The complete list of significant changes in duodenal gene expression obtained by whole 
genome microarray analysis for the following comparison: 
V dr null baseline vs. WT baseline 
gene assignment FoldChange adi. pvalue 
NM 18172911 Muc611 mucin 6 0.01747005 2.78E-59 
NM 009363 II Tff2 II trefoil factor 2 (spasmolytic protein 1) 0.01927562 2.78E-59 
NM 026860 II 1190003M12Rik II RIKEN eDNA 1190003M12 0.02821670 3.36E-28 
NM 011922 II Anxa1 0 II annexin A 10 0.034501448 5.04E-20 
NM 02633611 2310057J18Rik II RIKEN eDNA 2310057J18 0.023529273 2.60E-14 
NM 13318411 Slc5a4a II solute carrier family 5 8.201186911 8.20E-13 
ENSMUST00000073350 II Ctse II cathepsin E (Ctse) 0.104399282 3.55E-12 
NM 02859311 Cybrd1 II cytochrome b reductase 1 0.227837588 1.08E-11 
NM_001 081084 II Cubn II cubilin (intrinsic factor-cobalamin 
receptor) 5.363943522 1.75E-11 
NM 025467 II Gkn2 II gastrokine 2 0.02398303 2.09E-10 
NM 001033366 II Dpcr1 II diffuse pan bronchiolitis critical region 0.07719625 3.93E-10 
NM 001077424 II A4gnt II alpha-1 0.07988742 7.05E-10 
NM 031188 II Mup1 II major urinary protein 1 0.10453278 3.24E-08 
NM 025973 II Pgc 1/progastricsin (pepsinogen C) 0.09894057 3.24E-08 
NM 025466 II Gkn1 II gastrokine 1 0.03398676 5.22E-08 
NM 008647 II Mup2 II major urinary protein 2 0.10643236 5.29E-08 
NM 008647 II Mup2 II major urinary protein 2 0.10896920 7.26E-08 
NM 009362 II Tff1 II trefoil factor 1 0.04192548 1.32E-07 
NM 008647 II Mup2 II major urinary protein 2 0.11794654 1.83E-07 
NM 001045550 II Mup2 II major urinary protein 2 0.11 781678 2.56E-07 
NM 001045550 II Mup2 II major urinary protein 2 0.11935309 3.15E-07 
NM_022413 II Trpv6 II transient receptor potential cation 
channel 0.13015475 5.76E-07 
NM 021332 II Glp1 r II glucagon-like peptide 1 receptor 0.07855238 7.22E-07 
NM 010844 II Muc5ac II mucin 5 0.05660384 1.65E-06 
NM 001081078// Let //lactase 4.30155899 1.65E-06 
NM 145434 II N r1 d 1 II nuclear receptor subfamily 1 4.34941603 1.65E-06 
NM 023113 II Aspa II aspartoacylase (aminoacylase) 2 4.50334613 1.96E-06 
NM 001042712 II Amy2-1 II amyjase 2-1 0.18141119 1.98E-06 
NM 001042712 II Amy2-1 II amylase 2-1 0.18141119 1.98E-06 
NM 001042712 II Amy2-1 II amylase 2-1 0.18141119 1.98E-06 
NM 001042712 II Amy2-1 II amylase 2-1 0.18141119 1.98E-06 
NM 009669 II Amy2 II amylase 2 0.15934821 1.98E-06 
NM 001045550 II Mup2 II major urinary protein 2 0.13446752 1.98E-06 
NM 001024698 II Cpa2 II carboxypeptidase A2 0.13271512 3.30E-06 
NM 023219 II Slc5a4b II solute carrier family 5 5.12868280 3.30E-06 
NM 011036 II Pap II pancreatitis-associated protein 2.23110379 3.30E-06 
NM 007969 II Expi II extracellular proteinase inhibitor 0.15164079 4.49E-06 
NM 007860 II Dio1 II deiodinase 5.10719749 7.48E-06 
NM 008647 II Mup2 II major urinary protein 2 0.14355542 8.85E-06 
NM 009763 II Bst1 II bone marrow stromal cell antigen 1 4.34974844 1.21 E-05 
NM 008386 II lns1 II insulin I 0.15279525 1.33E-05 
XM 001477017 II LOC100046894 II similar to lgk-C protein 3.86183466 1.44E-05 
NM 009504 II Vdr II vitamin D receptor 0.31357283 1.45E-05 
NM 19925211 Unc93a II unc-93 homolog A (C. elegans) 4.3206215 3.76E-05 
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The complete list of significant changes in duodenal gene expression obtained by whole 
genome microarray analysis for the following comparison: 
V dr null baseline vs. WT baseline 
NM 007607 II Car4 II carbonic anhydrase 4 3.99433834 3.96E-05 
8C128471 II Unc93a II unc-93 homolog A (C. elegans) 4.27087551 4.47E-05 
NM 001045550 II Mup2 II major urinary protein 2 0.16491619 5.79E-05 
ENSMUST00000080885 II Dbp II 3.75745354 7.07E-05 
NM 013590 II Lyz II lysozyme 0.92222030 8.28E-05 
NM 008486 II Anpep II alanyl (membrane) aminopeptidase 2.65777403 8.67E-05 
NM 146198 II Slc5a11 II solute carrier family 5 3.73013222 0.00012729 
NM 013605 II Muc1 II mucin 1 0.15906580 0.00017299 
NM 133675 II 1110032A04Rik II RIKEN eDNA 1110032A04 0.13847562 0.00017389 
NM 175344 II Tmem16f II transmembrane protein 16F 4.00810019 0.00019840 
NM 001009546 II Naaladl1 II N-acetylated alpha-linked acid. 5.56544564 0.00020020 
ENSMUST00000047812 II Dpp4 II dipeptidylpeptidase 4 (Dpp4) 3.78380407 0.00020263 
8C129974 II Pla2g4c II phospholipase A2 0.20342232 0.00020702 
NM 001081215 II 8C013672 II eDNA sequence 8C013672 3.61245200 0.00021289 
NM 001012307 II Defcr23 II defensin related cryptdin 23 0.64361 771 0.00023103 
NM 001012307 II Defcr23 II defensin related cryptdin 23 0.64361 771 0.00023103 
NM 009127 II Scd1 II stearoyi-Coenzyme A desaturase 1 0.19572797 0.00025986 
NM 007850 II Defcr3 II defensin related cryptdin 3 0.69235211 0.00026254 
NM 007850 II Defcr3 II defensin related cryptdin 3 0.69235211 0.00026254 
NM 029639 II 1600029D21 Rik II RIKEN eDNA 1600029D21 0.15976842 0.00028923 
NM 013492 II Clu II clusterin 0.18821250 0.00030887 
NM 011783 II Agr2 II anterior gradient 2 (Xenopus laevis) 0.24771194 0.00035305 
NM 007850 II Defcr3 II defensin related cryptdin 3 0.70232151 0.00036360 
NM 025583 II Ctrb1 II chymotrypsinogen 81 0.24216203 0.00037328 
NM 017474 II Clca3 II chloride channel calcium activated 3 0.54678265 0.00039333 
NM 01 7399 II Fabp1 II fatty acid binding protein 1 2.63050644 0.00041867 
NM 026925 II Pnlip II pancreatic lipase 0.18014525 0.00050268 
8C061093 II 2210010C04Rik II RIKEN eDNA 2210010C04 gene 0.151 88741 0.0005131 7 
NM 008604 II Mme II membrane metallo endopeptidase 2.71201 555 0.000601 77 
NM 007643 II Cd36 II CD36 antigen 3.18084723 0.000601 77 
NM 025989 II Gp2 II glycoprotein 2 (zymogen granule membr.) 0.24405391 0.00068 
NM 177802 II Slc7a15 II solute carrier family 7 3.39864474 0.00073811 
NM 018830 II Asah2 II N-acylsphingosine amidohydrolase 2 3.35455778 0.00073811 
8C027527 II lapp II islet amyloid polypeptide 0.17749638 0.00081990 
NM 001038996 II Try1 0 II trypsin 10 0.17100693 0.00081990 
NM 001081310 II 201 0003H20Rik II RIKEN eDNA 201 0003H20 2.97425922 0.001 20473 
NM 009885 II Cel II carboxyl ester lipase 0.19728624 0.001 21 499 
NM 134072 II Akr1c14 II aldo-keto reductase fam ily 1 3.02753525 0.001 27240 
NM 029706 II Cpb1 II carboxypeptidase 81 (tissue) 0.17206824 0.00136462 
NM 008100 II Gcg II glucagon 0.20572990 0.00146894 
NM 025350 II Cpa1 II carboxypeptidase A 1 0.18659062 0.00167505 
NM 033612 II Ela1 II elastase 1 0.2569561 2 0.001 77088 
NM 011584 II Nr1 d2 II nuclear receptor subfamily 1 2.46028477 0.00181632 
ENSMUST00000033806 II Vsig1 II V-set and immu 0.16036354 0.00312132 
NM 028216 II Psca II prostate stem cell antigen 0.13506044 0.00390596 
NM 011259 II Reg3a II regenerating islet-derived 3 alpha 3.07176108 0.00483194 
NM 008360 II 1118 II interleukin 18 2.90460940 0.00531538 
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Vdr null baseline vs. WT baseline 
ENSMUST00000023820 II Fabp2 //fatty acid binding protein 2 2.09737262 0.00545217 
NM 011646 II Try4 II trypsin 4 0.18131316 0.00547880 
ENSMUST00000069800 II Fut211 fucosyltransferase 2 (Fut2) 0.26230618 0.00586791 
ENSMUST0000005741 0 II Fbln111 fibulin 1 (Fbln1) 2.82130787 0.00608967 
NM 01887411 Pnliprp1 II pancreatic lipase related protein 1 0.17649297 0.00608967 
ENSMUST00000058865 II Pdzk1 II PDZ domain containing 1 2.86784845 0.00679448 
NM 013697 II Ttr II transthyretin 0.27978811 0.00683306 
NM 001029935 II Trim38 II tripartite motif-containing 38 3.71000847 0.00694405 
NM_145424 II BC089597 II eDNA sequence BC089597 II 10 D3 
II 216454 3.10134342 0.00725440 
NM 001082976 II Tc2n II tandem C2 domains 0.21696727 0.00737180 
NM 019792 II Cyp3a25 II cytochrome P450 2.98136243 0.00836170 
NM 0197 41 II Slc2a5 II solute carrier family 2 2.33181374 0.00864126 
NM 001003405 II 1810049H19Rik II RIKEN eDNA 1810049H19 0.19936053 0.00880099 
ENSMUST00000031277 II Prkg2 II protein kinase 2.85337648 0.00881361 
NM 019792 II Cyp3a25 II cytochrome P450 3.01156862 0.00958223 
NM 02051811 Vsig2 II V-set and immunoglobulin domain 0.23832606 0.00989103 
NM 008904 II Ppargc1 a II peroxisome proliferative activated rec. 2.81746876 0.00993789 
NM 031197 II Slc2a2 II solute carrier family 2 2.30744151 0.01007046 
NM 139142 II Xtrp3s1 II X transporter protein 3 similar 1 gene 2.71230662 0.01276961 
NM 13914811 Clca411 chloride channel calcium activated 4 0.46366399 0.01283238 
NM 022411 II Slc13a2 II solute carrier family 13 2.70564159 0.01396868 
NM 009099 II Trim30 II tripartite motif protein 30 2.76072049 0.01407884 
NM 007919 II RP23-395H4.4 II elastase 2A 114 E1 1113706 0.23778684 0.01423963 
NM 019815 II Cldn18 II claudin 18 II 0.20724016 0.01440302 
NM 013806 II Abcc2 II ATP-binding cassette 2.23000850 0.01536195 
NM 199313// AY053573// eDNA sequence AY053573 3.41771022 0.01536195 
NM 023182 II Ctrlll chymotrypsin-like 0.25273854 0.01619867 
NM 009425 II Tnfsf1 0 II tumor necrosis factor (ligand) 2.84433391 0.01758792 
AF027131 II Muc3 II mucin 3 1.75315936 0.01904898 
NM 001024225 II Defcr24 II defensin related cryptd in 24 0.67961524 0.02015273 
NM 019810 II Slc5a1 II solute carrier family 5 1.62782443 0.02137025 
NM 178758 II Acsm5 II acyl-GoA synthetase member 5 3.18091254 0.02185137 
NM 007689 II Chad II chondroadherin 0.23455815 0.02267048 
NM 021353 II Slc26a3 II solute carrier family 26 0.45722137 0.02689101 
NM 010478 II Hspa1 b II heat shock protein 1 B 0.27128338 0.02690976 
NM 026947111810022C23Rik II RIKEN eDNA 1810022C23 2.72691809 0.02873092 
NM 011957 II Creb311 II cAMP respon. Elem. bind. prot. 3-like 1 0.28651191 0.03030682 
NM 001081137 II 201 0204N08Rik II RIKEN eDNA 201 0204N08 1.54545348 0.03068960 
NM 007 468 II Apoa4 II apolipoprotein A-IV 1.34036702 0.03068960 
NM 173388 II Slc43a2 II solute carrier family 43 2.65501427 0.03242977 
NM 011271 II Rnase1 II ribonuclease 0.25005237 0.03300215 
ENSMUST00000023328 II Retnlb II resistin like beta (Retnlb) 0.53050505 0.03862735 
ENSMUST00000030303 II Cyp2j6 II cytochrome P450 2.57155346 0.04121532 
BC060650 II Aldh4a1 II aldehyde dehydrogenase 4 family 2.55656463 0.04626171 
NM 027464115730469M10Rik II RIKEN eDNA 5730469M10 2.19434445 0.04759991 
NM 010639 II Klk1 II kallikrein 1 0.36384408 0.04775212 
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V dr null baseline vs. WT baseline 
NM_028341 II 2810439F02Rik II RIKEN eDNA 281 0439F02 
gene 2.49326872 0.04853589 
BC024697 II Apoc2 II apolipoprotein C-11 1.98646010 0.04901649 
BC039284 II Muc2 // mucin 2 0.63589496 0.05994525 
NM 001081663 II Btnl7 2.56727736 0.06034437 
ENSMUST00000075068 II Pepd II peptidase D (Pepd) 2.51893270 0.06072724 
ENSMUST00000025054 II Spdef II SAM pointed domain 0.29919539 0.06078031 
NM 026419 II Ela3 II elastase 3 0.29418322 0.06186280 
NM 001037842 II Cml3 II camello-like 3 2.92983724 0.06186280 
ENSMUST00000046233 II Bbox1 II butyrobetaine (gamma) 2.72412203 0.06527830 
NM 133775 II 1133 II interleukin 33 2.19224544 0.07130141 
NM 019631 // Tmem45a II transmembrane protein 45a 0.31920632 0.07401122 
NM 011128 II Pnliprp2 II pancreatic lipase-related protein 2 0.35032868 0.07705987 
ENSMUST00000025866 II Vldlr II very low density lipoprotein 
receptor 0.34018037 0.08077338 
NM 153506 II Clec2e II C-type lectin domain family 2 2.43664304 0.08614172 
NM 009801 II Car2 II carbonic anhydrase 2 0.44054038 0.08936203 
NM 008331 lllfit1 II interferon-induced protein 2.76191724 0.08977668 
NM 009155 II Sepp1 II selenoprotein P 2.31996564 0.09019386 
NM 14610111 Habp211 hyaluronic acid binding protein 2 0.34356553 0.09288956 
NM 001037842 II Cml3 II camello-like 3 2.80422705 0.0933689 
BC064446 II Casc4 II cancer susceptibility candidate 4 0.30068677 0.0933689 
NM 02781611 Cyp2u1 II cytochrome P450 2.65909900 0.1006185 
NM 194058 II Nlrp9b II NLR family 3.05435946 0.1006185 
NM 011463 II Spink411 serine peptidase inhibitor 0.60337206 0.1006185 
NM 177450 II Cndp1 II carnosine dipeptidase 1 2.57651149 0.1006185 
NM_153546 / Mboat1 I membr. Bnd. 0-acyltransferase dom. 
cont. 0.33076229 0.1006692 
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genome microarray analysis for the following comparison: 
Vd 11 Vd 11 b r r nu pregnancy vs. r nu ase me 
gene assignment FoldChanqe adi pvalue 
NM_028593 II Cybrd1 II cytochrome b reductase 
1 6.120796484 0 
XM_ 001477017 II LOC100046894 II similar to 
Igk-C 0.194693201 3.21E-18 
NM_ 011036 II Pap II pancreatitis-associated 
protein 0.364926724 1.54E-17 
NM_008732 II Slclla2 II solute carrier family 11 
(proton-coupled divalent metal ion transporters) 4.357052681 0 
NM_ 011260 II Reg3g II regenerating islet-derived 
3 gamma 0 .357380812 2.52E-13 
NM 010220 II Fkbp5 II FK506 bindinq protein 5 4.810803807 7.27E-10 
NM 001081084 II Cubn II cubilin 3.144371463 1.39E-09 
NM_022413 I I Trpv6 I I transient receptor 
potential cation channel 4.836569021 1.56E-07 
N M 008570 I I Mcptl I I mast cell protease 1 0.177368356 1.90E-07 
NM 007398 II Ada II adenosine deaminase 0.385993652 2.41E-06 
NM_ 011044 II Pck1 II phosphoenolpyruvate 
carboxykinase 1 0.340746708 1.48E-05 
NM 145474 II Cyp2d34 II cytochrome P450 3. 75830429 1.48E-05 
BC030378/I Slc38a1 II solute carrier family 38 2.582642546 1.48E-05 
NM_ 134005 II Enpp3 II ectonucleotide 
pyrophosphataselp hosphod iesterase 3 0.456800652 5.38E-05 
AF121081 II Slc37a2 II solute carrier family 37 
( glycerol-3- phosphate transporter) 2. 727759038 8.94E-05 
ENSMUST00000095541 II Susd2 II sushi domain 
containing 2 (Susd2) 0.331456829 8.94E-05 
NM 007643 II Cd36 II CD36 antiqen 0.509312565 0.000102785 
NM 008630 II Mt2 II metallothionein 2 2.349464459 0.000128643 
M17782 II lgk-V38 II immunoglobulin kappa 
chain variable 38(V38) 0.438945778 0.000152924 
NM 009903 I I Cldn4 I I claudin 4 0.464922575 0.001107139 
NM_001039562 II Ankrd37 II ankyrin repeat 
domain 37 3.127352469 0.001308457 
NM 207105 II H2-Ab1 II histocompatibility 2 1.598633517 0.001308457 
NM_028064 II Slc39a4 II solute carrier family 39 
(zinc transporter) 2.171937743 0.004393782 
BCO 10818 I I Sprr2a I I small proline-rich protein 
2A II 3 F1l3 45.2 eM II 20755 Ill BC099393 II 
LOC 100042514 I I hypothetical protein 
LOC100042514 II 3 F1 II 100042514 1. 988749457 0.004933078 
NM 009155 II Sepp1 II selenoprotein P 0.44892077 0.004933078 
NM_ 008571 II Mcpt2 II mast cell protease 2 II 14 
C3114 20.0 eM II 17225 Ill 
ENSMUST00000015576 I I Mcpt2 I I mast cell 
protease 2 (Mcpt2) 0.316326101 0.004933078 
NM_ 133675 I I 1110032A04Rik I I RIKEN eDNA 
1110032A04 gene II 3 E3 II 66183 Ill AF365876 3.082500491 0.004933078 
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I I 1110032A04Rik I I RIKEN eDNA 1110032A04 
gene II 3 E3 II 66183 
NM_011259 I I Reg3a I I regenerating islet-derived 
3 alpha II 6 C316 33.5 eM II 19694 Ill 
ENSMUST00000101272 II Reg3a II regenerating 
islet-derived 3 alpha (Reg3a) 0.450382837 0.004933078 
NM_199313 I I AY053573 II eDNA sequence 
AY053573 II 10 D3 II 380674 Ill 
ENSMUST00000077287 I I AY053573 I I eDNA 
sequence AY053573 (AY053573) 0.274387156 0.005164111 
NM_028247 II Slc16a10 II solute carrier family 16 
(monocarboxylic acid transporters) 0.480292374 0.013657821 
NM 029638 II Abp1 II amiloride binding protein 1 0.477382097 0.014907647 
NM_018830 I I Asah2 I I N-acylsphingosine 
amidohydrolase 2 0.49268721 0.014907647 
NM 016689 II Aqp3 II aquaporin 3 0.443522676 0.020582463 
NM 010378 II H2-Aa II histocompatibility 2 1.451263167 0.021569196 
BC099393 II LOC100042514 II hypothetical 
protein LOC100042514 1.854556384 0.022816924 
BC099393 II LOC100042514 II hypothetical 
protein LOC100042514 1.854556384 0.022816924 
AK008306 II 2010103J01Rik II RIKEN eDNA 
2010103J01 gene 0.567813795 0.025066917 
NM_017474 II Clca3 II chloride channel calcium 
activated 3 1.424921707 0.027133604 
NM_ 207624 I I Ace I I angiotensin I converting 
enzyme (peptidyl-dipeptidase A) 1 0.497894932 0.033131966 
NM 027872 II Slc46a3 II solute carrier family 46 0.497758459 0.041829041 
NM_026853 II Asb11 II ankyrin repeat and SOCS 
box-containing protein 11 2.460587282 0.041829041 
NM 009801 II Car2 II carbonic anhyd rase 2 1.847275217 0.041829041 
NM_026918 II 1810010M01Rik II RI KEN eDNA 
1810010M01 gene 1.460379772 0.04182904 1 
NM_ 199252 II Unc93a II unc-93 homolog A (C. 
elegans) 0.506478057 0.059743023 
NM_ 133894 II Ugt2b38 II UDP 
glucuronosyltransferase 2 family 0.505940194 0.063 167123 
NM_008486 II Anpep II alanyl (membrane) 
aminopeptidase 0.621230968 0.063358982 
ENSMUST00000066175 I I Abcg5 I I ATP-binding 
cassette 0.49614775 0.063358982 
U00478 II Dnase1 II deoxyribonuclease I 
deoxyribonuclease I (Dnase1) 0.403125255 0.063358982 
NM_011217 II Ptprr II protein tyrosine 
phosphatase 0.462060897 0.065369394 
NM 011575 II Tff3 II trefoil factor 3 1.54392742 0.065369394 
NM_025929 II 2010109103Rik II RIKEN eDNA 
2010109103 qene 0.618897411 0.074406175 
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NM 019571 // TspanS // tetraspanin 5 0 .535970157 0 .074406175 
BC070401 // Sgk1 //serum/glucocorticoid 
regulated kinase 1 2.149360098 0.080625796 
NM_ 177016 // Slc17a4 II solute carrier family 17 
(sodium phosphate) 0.430614235 0.085909499 
NM_ 001025573 // 2010107G12Rik // RIKEN eDNA 
2010107G12 qene 0.568385314 0 .087888829 
ENSMUST00000073350 // Ctse II cathepsin E 
(Ctse) 2.364568278 0.100161896 
NM 009026 II Rasd1 // RAS 2.321938218 0.111602411 
NM_ 009127 II Scd1 // stearoyi-Coenzyme A 
desaturase 1 3.207585772 0 .126707778 
NM 133995 // Upb1 // ureidopropionase 0.482472774 0.126707778 
NM 007468 II Apoa4 // apolipoprotein A-IV 0.822485326 0.13203257 
NM 001042605 // Cd74 II CD74 antiqen 1.433375945 0.139334994 
NM_001004184 II Slc28a1 //solute carrier family 
28 (sodium-coupled nucleoside transporter) 0 .576600387 0 .156833937 
NM_ 001029867 // Ugt2b36 // UDP 
glucuronosyltransferase 0.461741821 0 .167338872 
NM_ 001030291 // Enpp7 // ectonucleotide 
pyrophosphatase/phosphodiesterase 7 0.432880612 0 .170388428 
BC128471 // Unc93a // unc-93 homolog A (C. 
eleqans) 0 .538743519 0 .171153546 
NM_001029935 // Trim38 II tripartite motif-
containing 38 0.419777639 0 .171153546 
NM_001011790 // Olfr1382 II olfactory receptor 
1382 2.246118106 0 .171153546 
NM_009467 // Ugt2b5 // UDP 
glucuronosyltransferase 2 family 0.459374996 0 .176023503 
U28490 I I H2-Eb 1 I I histocompatibility 2 1.44783838 0 .182752634 
NM_001012306 II Hsd3b3 II hydroxy-delta-s-
steroid dehydrogenase 2.533205788 0. 191230299 
BC039284 I I Muc2 I I mucin 2 1.37447149 0.201677977 
BC028504 I I Ccl20 I I chemokine (C-C motif) 
ligand 20 2.214645926 0.206264102 
NM_ 023149 // Cndp2 // CNDP dipeptidase 2 
(metallopeptidase M20 family) 0.57289003 0 .229955102 
ENSMUST00000029076 I I Car3 I I carbonic 
anhydrase 3 2.88332321 0.254386067 
NM_ 026436 II Tmem86a II transmembrane 
protein 86A 0 .556995602 0.254386067 
NM_ 007409 II Adh1 //alcohol dehydrogenase 1 
(class I) 0. 73610361 0.254386067 
NM_ 011978 II Slc27a2 II solute carrier family 27 
(fatty acid transporter) 0.541446695 0 .284425108 
NM 011463 // Spink4 //serine peptidase inhibitor 1.234398517 0.288099845 
NM 172448// Rnf43 //ring finger protein 43 1.723543195 0.300959248 
NM 178661 II Creb312 //cAMP responsive 0.534638954 0 .327872365 
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element binding protein 3-like 2 
NM_009763 I I Bstl I I bone marrow stromal cell 
antigen 1 0.607238644 0.397043434 
NM_028610 II Dppa4 II developmental 
pluripotency associated 4 0.482665569 0.413424615 
ENSMUST00000102925 II Uap111 II UDP-N-
acteylglucosamine pyrophosphorylase 1-like 1 0.607234181 0.413424615 
NM_ 007969 I I Expi I I extracellular proteinase 
inhibitor 2.356571653 0.508349257 
NM 175606 I I Hopx I I HOP homeobox 1.900112033 0.532996437 
NM 001024714 II Cma2 II chymase 2 0.477770443 0 .532996437 
NM 146811 II Olfr910 II olfactory receptor 910 2.16903618 0.53578644 
NM 020010 II Cyp51 II cytochrome P450 1.857106275 0.53578644 
ENSM UST00000030408 I I Mfsd2 I I major 
facilitator superfamily domain containing 2 
(Mfsd2) 0.606406246 0.540126013 
NM 010281 II Ggh II gamma-glutamyl hydrolase 2.241582894 0.552893515 
NM 010281 II Ggh II gamma-glutamyl hydrolase 2.241582894 0.552893515 
NM_001033286 II Slc30a10 II solute carrier 
family 30 1.621158014 0.567399573 
AF045497 I I Igh-6 I I immunoglobulin heavy chain 
6 0.593047469 0.585080453 
NM_ 025968 I I Ltb4dh I I leukotriene B4 12-
hydroxydehydrogenase 0.556631262 0.585080453 
BC024348 II 1810030J14Rik II RIKEN eDNA 
1810030] 14 gene 1.989945419 0.593966682 
NM_001034865 II Nek10 II NIMA (never in 
mitosis gene a)- related kinase 10 0.529989939 0.627814254 
NM_ 176924 I I 9530053A07Rik I I RIKEN eDNA 
9530053A07 1. 743339339 0.63680537 
NM 026180 I I Abcg8 I I ATP-binding cassette 0.57627302 0 .669721707 
NM_029555 I I Gstk1 I I glutathione 5-transferase 
kappa 1 1.674602963 0.727016716 
NM_ 139142 II Xtrp3s1 II X transporter protein 3 
similar 1 0.603214874 0. 740784355 
NM 029494 I I Rab30 I I RAB30 0.438181746 0. 740784355 
NM_001009546 II Naaladl1 II N-acetylated alpha-
linked acidic dipeptidase-like 1 0.410618198 0.740784355 
NM_011783 II Agr2 II anterior gradient 2 
(Xenopus laevis) 1.477811247 0. 75587811 
NM_ 153783 I I Paox I I polyamine oxidase (exo-
N4-amino) 1.582987778 0 .776269388 
NM_008604 I I Mme I I membrane metallo 
endopeptidase 0.656235125 0.807241881 
NM 009992 II Cyp1a1 II cytochrome P450 0.258502939 0.808358151 
NM 010782 II Mcpt9 II mast cell protease 9 0.499582682 0.822362172 
NM 021467 II Tnni1 II troponin I 1.970041867 0.82685767 
NM 023219 I I Slc5a4b I I solute carrier family 5 0.564237844 0.833550467 
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(neutral amino acid transporters 
NM 015747 II Slc20a1 II solute carrier fam ily 20 0 .640422524 0 .87203211 
NM_001033324 II Zbtb16 II zinc finger and BTB 
domain containing 16 2.314356519 0.8720321 1 
ENSMUST00000080885 II Dbp II D site albumin 
promoter binding protein (Dbp) 0.64149821 0 . 900644927 
ENSMUST00000021530 I Hif1a I hypoxia inducible 
factor 1 0.612177903 0 .902049436 
NM_ 153506 I I Clec2e I I C-type lectin domain 
family 2 0.636172035 0.9 168243 
NM 012055 II Asns II asparagine synthetase 1.564792917 0.95 1767909 
NM_ 001033366 II Dpcr1 II diffuse 
panbronchiolitis critical region 1 2.198909891 0.98574 557 
NM_ 207208 II Clca6 II chloride channel Ca 
activated 6 0. 740085392 0.98574557 
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W T 1 WTb r ate pregnancy v s. ase me 
gene assiqnment FoldChanqe adj _pvalue 
NM_ 009363 II Tff2 II trefoil factor 2 (spasmolytic 
protein 1) 0.076079 3.63E-44 
NM 181729 I I Muc6 I I mucin 6 0 .0685669 4.19E-44 
NM_026860 II 1190003M12Rik II RIKEN eDNA 
1190003M12 0.0758995 1.38E-21 
NM 031188 II Mup1 II major urinary protein 1 0.0562791 3.04 E- 16 
NM 008647 II Mup2 II major urinary protein 2 0.0635273 1.48E-14 
NM 008647 II Mup2 II major urinary protein 2 0 .0747501 1.27E- 12 
NM 008647 II Mup2 II major urina ry protein 2 0.0792536 2.38E- 12 
NM_ 026336 II 2310057J18Rik II RIKEN eDNA 
2310057]18 0.0392125 5.05E- 12 
NM 001045550 II Mup2 II major urinarv protein 2 0.0856137 2.69E- 11 
NM 025973 I I Pqc I I proqastricsin ( pepsinoqen C) 0.086 1823 1.27E- 10 
NM 001045550 II Mup2 II major urinary protein 2 0 .0923848 1.56E-10 
NM 025466 II Gkn1 II gastrokine 1 0 .0328597 3.49E-09 
NM 001045550 II Mup2 II major urinary protein 2 0.1101184 8.97E-09 
NM 001077424 II A4qnt II alpha-1 0.1032305 1.21E-08 
NM 009362 I I Tff1 I I trefoil factor 1 0.0402426 1.29E-08 
NM 025467 I I Gkn2 I I gastrokine 2 0.0321301 1.67E-08 
NM 008647 II Mup2 II major urinary protein 2 0.1171555 4.96E-08 
NM 021332 I I Glp1r I I glucagon-like peptide 1 receptor 0.0827272 3.60E-07 
NM 001045550 II Mup2 II major urinary protein 2 0.130434 3.70E-07 
NM 010844 II Muc5ac II mucin 5 0.059077 9.30E-07 
NM_ 133894 II Ugt2b38 II UDP glucuronosyltransferase 
2 0.2049445 5.79E-06 
NM 009992 II Cyp1a1 II cytochrome P450 4.019687 0 .00039495 
NM 029494 I I Rab30 I I RAB30 4.4439749 0 .00041 76 
NM 011922 II Anxa10 II annexin A10 0 .4612434 0.00075875 
NM 145434 II Nr1d1 II nuclear receptor subfamily 1 3.7113902 0 .00104328 
NM 013492 II Clu II clusterin 0 .237617 0.0026941 
AF027131 I I Muc3 I I mucin 3 1.9422252 0 .00390347 
NM_ 001033366 II Dpcr1 II diffuse panbronchiol itis 
critical r 0.336 1816 0 .00634644 
NM 008732 II Slc11a2 II solute carrier fam ily 11 4.3317996 0 .01622183 
NM 007689 II Chad II chond roadherin 0.2340061 0.03560548 
NM 0198 15 I I Cldn18 I I claudin 18 0.210068 0.0370079 
NM 007969 I I Expi I I extracellular proteinase inhibitor 0.2985981 0 .0453826 
NM 013697 I I Ttr I I transthyretin 0.3135062 0.04834296 
NM 194058 II Nlrp9b II NLR family 3.4693963 0.05 178443 
NM 001039562 II Ankrd37 II ankyrin repeat domain 37 4 .3029713 0 .05 178443 
NM_022413 I I Trpv6 II trans. Rec. potential cation 
channel 0.3278776 0.05447083 
ENSMUST00000033806 II Vsig1 II V-set and 
immunoglobul 0.1976509 0.06687534 
ENSMUST00000073350 II Ctse II cathepsin E (Ctse) 0 .4356475 0.08248174 
NM 021353 II Slc26a3 II solute carrier fam ily 26 0 .4324279 0.08248174 
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NM 009606 II Acta1 II actin 3.0888921 0.09073478 
NM 133184 II Slc5a4a II solute carrier famil 5 5.277091 0.10061168 
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NM 009992 I I Cyp1a1 I I cytochrome P450 0.144750297 5.19E-22 
NM 001081084 I I Cubn I I cubilin 2.632802627 0 
NM 008570 I I Mcptl I I mast cell protease 1 0.084159735 6.53E-21 
NM 009669 I I Amy2 I I amylase 2 0.107816813 5.75E- 19 
NM 001042712 II Amy2-1 II amylase 2- 1 0.123989583 2.71E- 17 
NM 001042712 II Amy2-1 II amylase 2-1 0.123989583 2. 71E- 17 
NM 001042712 II Amy2-1 II amy_lase 2-1 0.123989583 2.71E-17 
NM 001042712 II Amy2-1 II amylase 2-1 0.123989583 2.71E-17 
NM 008571 I I Mcpt2 I I mast cell protease 2 0.129311353 6.58E-15 
NM 145474 I I Cyp2d34 II cytochrome P450 5.281988808 1.82E-11 
NM 001024698 II Cpa2 II carboxypeptidase A2 0.168303901 4.15E-11 
NM 026925 I I Pnlip I I pancreatic lipase 0.163160493 9.04E-11 
NM 001024714 II Cma2 II chymase 2 0.174880492 3.26E-09 
NM 025583 II Ctrb1 II chymotrypsinogen 81 0.215194531 9.66E-09 
NM 013590 I I Lyz I I lysozyme 0.405176762 1.18E-08 
NM 025350 I I Cpa 1 I I carboxypeptidase A1 0.229307957 4 .27E-08 
NM 010782 I I Mcpt9 I I mast cell protease 9 0.200963355 4.79E-08 
NM 033612 II Ela1 II elastase 1 0.220061251 2.11E-07 
NM 133184 I I Slc5a4a I I solute carrier family 5 2.045040529 3.32E-07 
NM 026419 II Ela3 II elastase 3 0.264457785 5.86E-07 
NM 007919 II RP23-395H4.4 II elastase 2A 0.217514775 2.20E-06 
NM_ 133894 I I Ugt2b38 I I UDP 
glucuronosyltransferase 2 family 3.441398623 2.90E-06 
NM 029706 II Cpb1 II carboxypeptidase 81 (tissue) 0.243191637 3.83E-06 
NM_018874 I I Pnliprp1 I I pancreatic lipase related 
protein 1 0.284470405 3.83E-06 
NM 146466 I I Olfr165 I I olfactory receptor 165 3.340979451 5.01E-06 
NM_025929 II 2010109103Rik II RIKEN eDNA 
2010109103 gene 0.323773611 8.60E-06 
NM 207105 II H2-Ab1 II histocompatibility 2 2.125903906 1.85E-05 
NM 011851 II Nt5e II 5' nucleotidase 0.268256237 2.30E-05 
NM 010855 II Myh4 II myosin 0.174464373 3.67E-05 
NM 009504 I I Vdr I I vitamin D receptor 0.318740422 3.81E-05 
NM 008386 I I Ins1 I I insulin I 0 .262650899 4.59E-05 
NM 011922 II Anxa10 II annexin A10 0.123263137 4.84E-05 
NM_033149 II B3galt5 II UDP-Gal:betaGicNAc beta 
1 0.202186107 4.84E-05 
NM 029494 II Rab30 II RAB30 0.308323186 5.43E-05 
NM 023182 I I Ctrl I I chymotrypsin- like 0.232202136 5.67E-05 
NM 009363 I I Tff2 I I trefoil factor 2 0.170749897 0.000131238 
NM_001081070 II Pdia2 II protein disulfide 
isomerase associated 2 0.270424762 0.000176361 
NM 009606 I I Acta 1 I I actin 0.317530244 0.000225045 
NM_ 175344 II Tmem16f II transmembrane protein 
16F 2.3812495 0.000370033 
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NM 001081078 I I Let I I lactase 2.215072107 0.000397973 
NM 0078S1 II DeferS II defensin related cryptdin S 0.32921920S 0.000803S24 
NM 177610 I I Duox2 I I dual oxidase 2 0.19841SS8 0.000803S24 
NM 0078S1 II DeferS II defensin related cryptdin S 0 .337S7209S 0 .001430497 
BC061093 II 2210010C04Rik II RIKEN eDNA 
2210010C04 0.291147872 0.0016S8422 
NM_008012 I I Akr1b8 I I aldo- keto reductase family 
1 0.2826976S6 0.001749432 
NM 001082S31 I I Pla2g2a I I phospholipase A2 0.290720642 0.0018374S8 
NM 02S989 I I Gp2 I I glycoprotein 2 0.306901732 0.0018S2824 
NM 010378 II H2-Aa II histocompatibility 2 1.83S8660S2 0.001943024 
NM 0078S1 I I DeferS I I defensin related cryptdin S 0.3470340S1 0.002128099 
BC061SOS II Cyp2d9 II cytochrome P4SO 2.81S8844S7 0.002167262 
NM_ 00100340S II 1810049H19Rik II RIKEN eDNA 
1810049H19 gene 0.338736238 0 .00223S172 
NM 0078S1 II DeferS II defensin related cryptdin S 0.3S4479134 0 .002929417 
NR 003SS2 II Cyp2d13 II cytochrome P4SO 2.9319063S9 0.002972871 
ENSMUST00000071646 II Rdh16 II retinol 
dehydrogenase 16 0.36S801646 0 .003037992 
NM_001004184 I I Slc28a1 I I solute carrier family 
28 (sodium-coupled nucleoside transporter) 2 .S3S691468 0 .0031471S6 
U28490 I I H2- Eb 1 I I histocompatibility 2 1.9S2613941 0 .003791021 
M17782 II Igk-V38 II immunoglobulin kappa chain 
variable 38(V38) 0.44S 149626 0 .0038SS784 
NM 007398 II Ada II adenosine deaminase 0.4011S6SS3 0 .003868697 
BC129974 I I Pla2g4c I I phospholipase A2 0 .2440844S2 0.004S12411 
NM_00104260S II Cd74 II CD74 antigen (invariant 
polypeptide of major histocompatibility complex 1.92S183374 O.OOSS80861 
NM 207S68 I I Olfr12S2 I I olfactory receptor 12S2 0.3S7S48886 O.OOS8S2911 
BC027S27 I I lapp I I islet amyloid polypeptide 0.3202S137 0.007068486 
NM_199313 I I AY053573 I I eDNA sequence 
AY053573 0.380915976 0.010325867 
ENSMUST00000023328 I I Retnlb I I resistin like beta 0.330681868 0 .012488S91 
NM 028089 II Cyp2cSS II cytochrome P4SO 2.4S1198104 0.0126918S4 
NM 009903 I I Cldn4 I I claudin 4 0.416058835 0.017892917 
ENSMUST00000087012 I I Slc22a7 I I solute carrier 
family 22 (organic anion transporter) 2 .304S80988 0.020202182 
NM_001012306 II Hsd3b3 II hydroxy-delta- s-
steroid dehydrogenase 2. 721600478 0 .022804121 
NM_007844 I I Defcr-rs1 I I defensin related 
sequence cryptdin peptide (paneth cells) 0 .382182492 0.022839009 
NM_007844 I I Defcr- rs1 I I defensin related 
sequence cryptdin peptide (paneth cells) 0 .38110S298 0 .023S3S089 
NM_023219 I I SlcSa4b I I solute carrier family S 
(neutral amino acid transporters 2 .092S48S2 0 .023 S3S089 
NM_011921 II Aldh1a7 II aldehyde dehydrogenase 
family 1 2.2S7494199 0.023903424 
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NM 009394 II Tnnc2 II troponin C2 0.401891089 0 .024712789 
NM_ 013467 II Aldh1a1 II aldehyde dehydrogenase 
family 1 2.167620942 0.026923285 
NM_ 145424 I I BC089597 I I eDNA sequence 
BC089597 2.24890717 0.027 11761 
NM 013811 I I Dnahc8 I I dynein 2.343095921 0 .028117789 
NM 001039545 II Myh2 II myosin 0 .359242086 0 .028320723 
ENSMUST00000071886 II AY761184 II eDNA 
sequence AY761184 0.430971342 0.032980916 
NM 007818 II Cyp3a11 II cytochrome P450 2.014681295 0.035982979 
NR 003146 II Defa-ps1 II defensin 0.412739885 0.039048153 
NM 133775 I I !133 I I interleukin 33 2.205855462 0.039048153 
NM_ 178758 II Acsm5 II acyi-CoA synthetase 
medium-chain family member 5 II 7 F2 II 272428 
Ill ENSMUST00000066465 II Acsm5 II RIKEN eDNA 
C730027J19 gene (C730027J19Rik) 2.242711992 0 .044485172 
NM 009999 II Cyp2b10 II cytochrome P450 2.181679635 0.04782008 
NM 008387 II Ins2 II insulin II 0.414741808 0 .050187809 
NM 007850 II Defcr3 II defensin related cryptdin 3 0.4865402 0.050187809 
NM 007850 I I Defcr3 I I defensin related cryptdin 3 0.4865402 0.050187809 
NM 007504 II Atp2a1 II ATPase 0.326970427 0 .050294971 
NM 178711 I I Plscr4 I I phospholipid scramblase 4 2 .252201592 0.05267649 
NR 003146 II Defa-ps1 II defensin 0.410552609 0 .053215284 
NM 011271 II Rnase1 II ribonuclease 0.46264114 0.054697354 
NM_ 001024225 II Defcr24 II defensin related 
cryptdin 24 0.426518272 0.056585119 
ENSMUST00000099472 II Cyp2c68 II cytochrome 
P450 1. 985700378 0 .057232405 
NM 009430 II Prss2 II protease 0.438806909 0.06243781 
NR 003146 II Defa-ps1 II defensin 0.423467943 0.063388438 
NM_ 001033875 I I Ctrc I I chymotrypsin C 
(caldecrin) 0.418630142 0.066139322 
NM_ 023113 II Aspa II aspartoacylase 
(aminoacylase) 2 2.168360691 0.067569894 
NM_022413 I I Trpv6 I I transient receptor 
potential cation channel 1.919931529 0.068088318 
NM 009043 I I Reg2 I I regenerating islet-derived 2 0.324583367 0.068679867 
NM 181541 II Caprin2 II caprin family member 2 2.208558616 0.068711881 
NM 007850 II Defcr3 II defensin related cryptdin 3 0 .497610065 0 .068711881 
NR 003146 II Defa-ps1 II defensin 0.43951884 0 .077515192 
BC001996 II H2-DMa II histocompatibility 2 1.952197829 0.080778886 
AF045503 I I EG434609 I I predicted qene 0.47549364 0.081097758 
NM_ 029639 I I 1600029D21Rik I I RIKEN eDNA 
1600029D21 0.305089058 0.090469903 
NM_ 010416 II Hemtl II hematopoietic cell 
transcript 1 0 .33510227 0 .094701369 
NM 008885 II Pmp22 II peripheral myelin protein 0.653651719 0 .096796679 
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APPENDIXB 
Further analysis of the duodenal microarray data. 
Similarities and differences of changes in gene expression between statistical 
comparisons. 
Bl. V dr null pregnane vs. WT pregnancy 
Decreased Increased 
NM_009669 II Amy2 II amylase 2 NM_022413 I I Trpv6 I I transient receptor 
NM_001042712 II Amy2-1 II amylase 2-1 potential cation channel 
NM_001024698 II Cpa2 II carboxypeptidase 
A2 
NM_026925 I I Pnlip I I pancreatic lipase 
NM_025583 II Ctrb1 II chymotrypsinogen B1 
NM_013590 II Lyz II lysozyme 
NM_025350 II Cpa1 II carboxypeptidase A1 
NM_033612 II Ela1 II elastase 1 
NM_026419 II Ela3 II elastase 3 
NM_007919 II RP23-395H4.4 II elastase 2A 
NM_029706 II Cpb1 II carboxypeptidase B1 
(tissue) 
Cl) NM_018874 II Pnliprp1 II pancreatic lipase 
~ related protein 1 
·- "'0 .......... Cl) Cl) NM_009504 II Vdr II vitamin D receptor II 15 
rfJ rfJ 
ell (\j F1 
..0 Cl) NM_008386 I I Ins1 I I insulin I f-; 1-< (.) NM_011922 II Anxa10 II annexin AlO ~ Cl) Q NM_023182 II Ctrl II chymotrypsin-like 
u5 N M_009363 I I Tff2 I I trefoil factor 2 ;;;. (spasmolytic protein 1) Cl) 
.5 NM_029639 II 1600029D21Rik II RIKEN eDNA 
v BC061093 II 2210010C04Rik II RIKEN eDNA 
rfJ (\j NM_025989 II Gp2 II glycoprotein 2 (zymogen 
..0 granule membrane) 
.......... BC027527 II lapp II islet amyloid polypeptide ::; 
~ ENSMUST00000023328 II Retnlb II resistin like 
~ beta (Retnlb) ~ NM_001012307 II Defcr23 II defensin related 
cryptdin 23 
NM_011271 I I Rnase1 I I ribonuclease 
NM_007850 I I Defcr3 I I defensin related 
cryptdin 3 
NM_001081084 II Cubn II cubilin (intrinsic 
NM_199313 I I AY053573 I I eDNA factor-cobalamin receptor) 
"'0 sequence AY053573 NM_ 133184 II Slc5a4a II solute carrier family 5 
Cl) 
rfJ NM_001081078 I I Let I I lactase (\j 
Cl) NM_ 023219 II Slc5a4b II solute carrier family 5 
1-< NM_133775 I I 1133 I I interleukin 33 (.) 
s::::: NM_178758 I I Acsm5 I I acyi-CoA synthetase ....... 
medium-chain family member 5 
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APPENDIXB 
Further analysis ofthe duodenal microarray data. 
Similarities and differences of changes in gene expression between statistical 
comparisons. 
B2. V dr null pregnancy vs. V dr null baseline 
Decreased Increased 
<!) NM_133894 II Ugt2b38 II UDP NM_022413 I I Trpv6 I I transient receptor 
.s 
"C) glucuronosyltransferase 2 family potential cation channel ~ <!) ENSMUST00000073350 II Ctse II cathepsin E Vl Vl 
<:1:1 (1j 
..0 <!) 
t-< 1-< (.) 
~ <!) Q 
ui 
> 
;>-. 
(.) § 
"'d NM_008732 II Slclla2 II solute carrier family 11 s:: 
bJ) <!) NM_ 001039562 II Ankrd37 II ankyrin repeat 
<!) Vl 
1-< (1j domain 37 
0.. <!) 1-< 
t-< (.) s:: ~ ....... 
B3. Vdr null pregnancy vs. Vdr null baseline 
Decreased Increased 
NM_028593 II Cybrdl II cytochrome b reductase 
1 
"'d NM_022413 I I Trpv6 I I transient receptor 
<!) 
Vl potential cation channel (1j 
<!) NM_017474 II Clca3 II ch loride channel calcium 
1-< 
activated 3 (.) 
<!) <!) NM_009801 II Car2 II carbonic anhydrase 2 
.s Q ENSMUST00000073350 II Ctse II cathepsin E 
~ 
Vl (1j 
..0 
t-< 
~ XM_001477017 II LOC100046894 II similar to 
ui Igk-C protein NM_001081084 II Cubn II cubilin (intrinsic 
> NM_Oll036 I I Pap I I pancreatitis-associated factor-coba lamin receptor) 
<!) protein s:: 
...... NM_007643 II Cd36 II CD36 antigen ~ NM_153506 II Clec2e II C-type lectin domain Vl 
<:1:1 family 2 
..0 "C) 
-
Q) NM_011259 I I Reg3a I I regenerating islet-
-
Vl 
:::::1 (1j derived 3 alpha 
s:: Q) NM_199313 I I AY053573 I I eDNA 1-< ~ (.) s:: sequence AY053573 
::::::: ....... NM_018830 11 Asah2 II N-acylsphingosine 
amidohydrolase 2 
NM_199252 II Unc93a II unc-93 homolog A 
(C. elegans) 
NM_008486 II Anpep II alanyl (membrane) 
aminopeptidase 
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APPENDIX B 
Fmther analysis ofthe duodenal microarray data. 
Similarities and differences of changes in gene expression between statistical 
comparisons. 
B4. V dr null pregnancy vs. V dr null baseline 
Decreased Increased 
NM_008570 II Mcptl II mast cel l protease 1 
NM_008571 II Mcpt2 II mast cell protease 2 
G- "'d NM_007398 II Ada II adenosine deaminase Q Cl) M17782 II Igk-V38 II immunoglobulin kappa 
<:1:1 Vl chain variable 38 <:1:1 ~ Cl) NM_009903 I I Cldn4 I I claudin 4 1-< Cl) (.) NM_199313 I I AY053573 I I eDNA sequence a Cl) Cl AYOS3573 t-< NM_025929 II 2010109I03Rik II RIKEN eDNA ~ 2010109103 gene 
ui 
;> 
G NM_ 133894 II Ugt2b38 II UDP NM_ 1454 74 I I Cyp2d34 I I cytochrome P450 s::: NM_ 001081084 I I Cubn I I cubilin (intrinsic 
<:1:1 glucuronosyltransferase 2 family 
~ factor-cobalamin receptor) "'d NM_ 010378 I I H2-Aa I I histocompatibility 2 Cl) Cl) a Vl NM_ 022413 I I Trpv6 I I transient receptor <:1:1 
......... Cl) potential cation channel 
"5 1-< (.) NM_ 207105 I I H2-Ab1 I I histocompatibility 2 s::: s::: 
~ ........ ;:::: 
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